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HoxA9 is frequently overexpressed in acute myeloid leukemia, myelodysplastic 
syndrome and a subset of acute lymphoblastic leukemia. In mouse models, HoxA9 has 
been shown to promote leukemogenesis. In spite of a central role in initiating leukemia, 
and in acting as a cofactor to promote leukemic cell growth and survival, the mechanistic 
pathways altered by HoxA9 overexpression that promote the growth and survival of 
leukemia, are not well defined. We have developed a stromal cell dependent model of 
human B-lineage ALL with conditional HoxA9 activity. The HoxA9-negative pre-B cell 
ALL cell line, BLIN-2, was stably transduced with a retrovirus bearing HoxA9 fused to 
the hormone binding domain of the human estrogen receptor. HoxA9 activity is 
stimulated by the addition of 4-hydroxytamoxifen to the growth medium. BLIN-2 cells 
have an absolute dependence on stromal cell contact for growth and survival, which 
permits the testing of the HoxA9 mediated effects in the context of the tumor 
microenvironment. Induction of HoxA9 activity in BLIN-2 resulted in increased 
proliferation in the absence of stromal cell support and induction of surface expression of 
IGF-1R. Through the use of specific IGF-1R inhibitors we demonstrated that the 
proliferative response upon HoxA9 stimulation was the result of signaling through the 
induced IGF-1R. In addition to promoting stromal cell independent proliferation, 
enforced induction of HoxA9 activity promoted apoptotic resistance to stromal 
cell/growth factor withdrawal. Inhibition of IGF-1R signaling did not abrogate the 
anti-apoptotic effects of HoxA9, but did result in decreased proliferation. Models of 
IGF-1R typically attribute anti-apoptotic effects of IGF-1R signaling to Akt signaling, 
whereas the proliferative effects are mediated via the ERK pathway. No changes in Akt 
phosphorylation were observed in BLIN-2 cells with activated HoxA9, but levels of 
phospho-ERK were increased. These results are consistent with a role for HoxA9 
induction of IGF-1R promoting proliferation, but not apoptotic resistance. Overall, these 
data indicate that enforced expression of HoxA9 in leukemia promotes proliferation via 
an IGF-1R dependent pathway and that HoxA9 promotes apoptotic resistance to stromal 
cell/growth factor withdrawal through a pathway that is independent of IGF-1R signaling. 
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CHAPTER 1: Introduction 
1.1 Hematopoiesis: A Brief Overview 
 Hematopoiesis is the formation of the blood’s cellular components. Unlike 
embryogenesis, which occurs only once at the beginning of life, hematopoiesis is a self 
renewing process that occurs indefinitely throughout the life span of a healthy individual. 
All of the blood cells of an organism are derived from pluripotent hematopoietic stem 
cells (HSCs) residing in the bone marrow. HSCs give rise to all cells of the myeloid and 
lymphoid lineages (Fig. 1) (1). HSCs are categorized by a common protein expression 
profile. Most notably, HSCs express the cell adhesion molecule CD34 and lack 
expression of the cell surface molecule CD38 (1). CD34 is the ligand for L-selectin and 
CD38 is an NAD glycohydrolase that augments cell proliferation. As HSCs become 
committed to different blood cell lineages they lose expression of CD34 and gain 
expression of CD38 (1). 
 HSCs undergo two types of cellular division in the stem cell niche; symmetrical 
and asymmetrical. Symmetrical division gives rise to two identical daughter cells, both 
remaining in the niche as stem cells. Asymmetrical division gives rise to one HSC and 
one of two committed progenitor cells, the myeloid stem cell (MSC) or the common 
lymphoid progenitor (CLP) (1). The HSC daughterremains in the niche as a stem cell 
and the committed progenitor cell leaves the niche to produce alarge number of progeny. 
The MSC differentiates through the myeloid lineage specific programs to give rise to all 
of the cells of the myeloid lineage, while the CLP gives rise to all of the cells of the 
lymphoid lineage.  
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Figure 1: An Overview of Hematopoiesis. Hematopoietic stem cells residing in the 
bone marrow differentiate into a myeloid stem cell or a common lymphoid progenitor. 
The myeloid stem cell gives rise to all the mature cells of the myeloid lineages, including: 
platelets (megakaryocytes), neutrophils, eosinophils, basophils, macrophages, and 
erythrocytes (not listed). The common lymphoid progenitor gives rise to cells of the 
lymphoid lineages, including: natural killer cells (NK), plasma cells, memory B-cells, 
helper T-cells, and cytotoxic T-cells. Dendritic cells (not shown) are derived from both 
the myeloid and lymphoid lineages. Leukemias can occur at any stage during 
hematopoiesis, leading to developmental arrest and uncontrolled proliferation. Acute and 
chronic myeloid leukemia (AML/CML) occur in cells of the myeloid lineages, and acute 
and chronic lymphocytic leukemia (ALL/CLL) occur in cells of the lymphoid lineages. 
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 Myeloid lineages. The myeloid lineage consists of both red and white blood cells. 
Red blood cells, or erythrocytes, are involved in the transport of O2 and CO2, bound to 
hemoglobin, to and from the tissues of the body, respectively. The white blood cells, or 
leukocytes, are comprised of a diverse group of cell types that function primarily to 
combat infections and assaults to the immune system. Leukocytes can be classified into 
three main categories: granulocytes, monocytes, and lymphocytes.  
There are three classes of granulocytes: neutrophils, basophils, and eosinophils. 
These cells are characterized by the presence of numerous granules within their 
cytoplasm which consist of lysosomes and secretory vesicles. Granulocytes are relatively 
short lived cells whose numbers increase during immune responses. Neutrophils are the 
most numerous of the granulocytes and play an important role in the innate immune 
response. The innate immune response defends the host from infection from organisms in 
a non-specific manner. Neutrophils eliminate many foreign pathogens by phagocytosis, a 
process involving internalization and degradation of foreign material by enzymes 
contained within the lysosomes. The function of eosinophils is not entirely understood. 
They are thought to play a major role in host defense against parasite infestation, 
although this role remains debatable (2). Basophils are the least abundant of the 
granulocytes. They act as the chief effector cells of allergic responses and as purveyors of 
various allergy-associated mediators such as histamine (3). 
Along with neutrophils, macrophages are one of the three phagocytic cells of the 
immune system. Macrophages, or mononuclear phagocytes, are mature monocytes whose 
main function is to ingest and process senescent erythrocytes. This function is important 
for heme and bilirubin metabolism. They are also involved in the removal of cellular 
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debris generated during tissue remodeling and clearance of cells that have undergone 
apoptosis (4). Furthermore, macrophages are important immune effector cells. As part of 
the innate immune response, macrophages scavenge the tissues of the body for invading 
pathogens to ingest and kill. They also play important regulatory and effector roles in 
adaptive immune responses (5). During adaptive immune responses, peptides derived 
from microorganisms that have been engulfed and degraded by macrophages are 
presented by major histocompatibility complex (MHC) class II molecules to T-cells (5). 
Macrophages stimulate the clonal expansion of T-cells through antigen presentation.  
Megakaryocytes give rise to circulating platelets involved in the formation of 
blood clots. Megakaryocytes are 10 – 15 times larger than a typical red blood cell, hence 
their name (6). Dendritic cells (not shown in Fig. 1), the last of the phagocytic cells of the 
immune system, are actually derived from both the myeloid and lymphoid lineages and 
are the most potent stimulators of the adaptive immune response (7). As with 
macrophages, once an immature dendritic cell recognizes a pathogen the dendritic cell 
phagocytoses the pathogen and degrades it into smaller fragments that can be presented 
to B and T-cells in the spleen and lymph nodes. 
Innate immunity is the first defense against invading pathogens and depends on 
germ-line encoded pattern recognition receptors (PRRs) on immune cells that recognize 
highly conserved pathogen-associated molecular patterns (PAMPs) found within classes 
of microbes (8). The adaptive or “specific” immune response is mediated primarily by B 
and T-lymphocytes. B and T-lymphocytes have a diverse repertoire of antigen receptors 
due to immunoglobulin (Ig) gene rearrangements. Ig gene rearrangements give rise to a 
limitless number of receptors capable of recognizing the antigenic component of any 
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potential pathogen or toxin (8). Activation of B and T-cells via antigen-mediated binding 
to Ig receptors initiates cell-mediated (T-cell) and humoral (B-cell) immune responses, 
directed by secreted antibodies (8).  
 Lymphoid lineages. The lymphoid lineages are comprised of B (bursal-derived), 
T (thymus-derived), and natural killer (NK) cells. Unlike B and T-cells, NK cells form 
part of the innate immune response. NK cells are large granular cells that kill a target cell 
“naturally” in a spontaneous fashion that does not require priming and is not restricted by 
the target cell’s expression of MHC molecules (9). NK cells recognize virally infected or 
transformed cells, due to a release of cytokines, and kill them via perforin/granzyme 
release or death receptor-related pathways (9). NK cells also secrete cytokines and 
chemokines that influence the host’s immune response. Interferon-gamma (INF-γ) release 
by NK cells activates antigen presenting cells (APC) (i.e. dendritic cells, macrophages, 
and B-cells) to upregulate expression of MHC class I molecules, induces macrophage 
killing of intracellular pathogens, inhibits proliferation of virus infected cells, and shapes 
the cellular (i.e. TH1; see below) immune response (9). Thus, NK cells are at the interface 
between innate and adaptive immunity. 
 T-cells develop from CLPs in the bone marrow (BM) and migrate to the thymus 
where they mature. Once positive selection of non-self-reactive T-cells has been 
completed in the thymus, the mature T-cells enter the bloodstream and recirculate 
between the blood and peripheral lymphoid tissue as naïve T-cells. When a naïve T-cell 
encounters its specific antigen, it is induced to proliferate and differentiate into a primed 
effector T-cell capable of contributing to the removal of antigen. Becoming a primed 
effector T-cell requires T-cell receptor (TCR)-mediated recognition of foreign antigen 
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bound to self MHC class I or II molecules with simultaneous co-stimulatory signals from 
professional APCs. A primed effector T-cell will differentiate into a cytotoxic T-cell, that 
kills infected target cells, or a helper T-cell. There are two types of helper T-cell, called 
TH1 and TH2. TH1 cells activate macrophages to kill invading pathogens and induce 
cell-mediated immunity and cytotoxic T-cell activity. TH2 cells initiate the humoral 
immune response by activating naïve antigen-specific B-cells to produce IgM antibodies 
that cause the destruction of extracellular microorganisms and prevent the spread of 
intracellular infections. 
 B-cells, like T-cells, are derived from CLPs in the BM. However, B-cell 
development (see B-cell development) occurs in the BM. As B-lineage cells mature they 
migrate out of the BM into lymphoid follicles of the spleen and lymph nodes, where they 
encounter and respond to T-cell dependent foreign antigens bound to follicular dendritic 
cells (FDC). Like T-cells, B-cells have specific cell surface receptors encoded by the Ig 
superfamily of genes known as the B-cell receptor (BCR). Antigen-mediated engagement 
of the BCR results in the transmission of signals directly to the interior of the cell, 
leading to rapid proliferation and differentiation of mature B-cells into antibody secreting 
plasma cells or memory B-cells. Additionally, binding of antigen to the BCR results in 
the internalization and degradation of antigen which is then presented on the surface of 
the cell as peptides bound to MHC class II molecules.  
Antigen induced B-cell differentiation and proliferation result in a process known 
as the germinal center (GC) reaction. GCs are areas in follicular regions of secondary 
lymphoid organs where antigen primed B-cells proliferate extensively. Antigen specific 
B-cells must have bound, processed, and presented antigenic peptide-MHC class II 
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complexes to initiate the TH-cell-dependent GC reaction (10). The main purpose of the 
GC reaction is development of B-cell memory. During GC reactions BCR diversification 
occurs via the processes of somatic hypermutation (SHM) and affinity maturation. 
Somatic hypermutation occurs due to individual point mutations in the variable regions of 
the Ig genes (11). This process results in the generation of variant Igs, some of which 
bind to antigen with greater affinity, allowing for increased affinity of the antibody 
response. Another phenomenon of the GC reaction, known as affinity maturation, leads 
to the development of antibodies with greater antigen affinity. Briefly, at the early stages 
of an immune response, B-cells with relatively low affinity for antigen become activated 
to produce antibodies and proliferate. The low affinity antibodies will bind to and clear 
antigen, leaving only those B-cells with receptors of the highest affinity to capture 
antigen. Consequently, the higher affinity B-cells out compete low affinity B-cells for 
antigen and are clonally selected for to dominate a secondary immune response. This 
process is repeated leading to the production of antibodies with even greater affinity in a 
tertiary response. 
Another modification of the Ig genes that occurs during a humoral immune 
response is known as isotype or class switching. Isotype switching does not change the 
specificity of an antibody, but does change the effector function of the antibody. There 
are five distinct antibody isotypes: IgM, IgG, IgD, IgA, and IgE. The different isotypes 
result from recombination of DNA encoding constant regions (C-region) of Ig genes. 
IgM is the first class of antibody to appear during an immune response, IgG is the most 
abundant antibody in the serum and lymphatic system. IgA is involved in mediating 
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mucosal immunity, IgE is involved in allergic responses. The function of IgD in shaping 
a humoral immune response is still not completely understood (12).  
1.1.3 B-Cell Development: An Overview  
B-cell development is characterized by the expression of B-lineage restricted 
genes, the presence of cell surface markers and the ordered rearrangements of the heavy 
and light Ig genes to produce functional antigen receptors. The earliest recognizable 
B-lineage cell is the pro-B cell, or progenitor B-cell, derived from the multipotent CLP 
(Fig. 2). Maturation and lineage commitment of a CLP into a pro-B cell is dependent on 
upregulation of E2A and de novo expression of Pax5 transcription factors (13). Pro-B 
cells are characterized by the expression of the earliest B-lineage surface markers, CD19 
and CD45R. The expression of CD19 and CD45R are maintained throughout B-cell 
development with the exception of mature plasma cells (14). Rearrangements of the Ig 
heavy chain variable (VH), diversity (DH), and joining (JH) regions occur at the pro-B cell 
stage of development. DH to JH joining occurs in early Pro-B cells followed by VH to DJH 
joining in late pro-B cells. Rearrangements of the heavy chain loci are mediated by 
recombinase activating gene 1 (RAG-1) and RAG-2 enzymes (15). Pro-B cells also 
express terminal deoxynucleotidyl transferase (TdT), a polymerase that adds nucleotides 
to the rearranging heavy chain segments. The addition of extra nucleotides generates 
additional diversity of the B-cell antigen receptor repertoire.  
At the pro-B cell stage of development, rearrangement of the heavy chain is 
completed. In addition, during the pro-B cell stage, cells express Igα and Igβ chain 
components of the antigen receptor, as well as the components of the surrogate light 
chain (ΨLC), encoded by the VpreB and λ5 (mouse) or 14.1 (human) genes (16,17). On- 
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Figure 2: Early stages of B-cell development. B-cells are derived from multipotent 
common lymphoid progenitors (CLP) residing in the BM. During the transition from the 
CLP to the progenitor B-cell (pro-B cell) stage, cells are characterized by the expression 
of CD34, recombinase activating genes 1 and 2 (RAG-1, -2) and are actively undergoing 
D to J heavy chain rearrangement, mediated by RAG-1 and 2. At the pro-B cell stage 
cells have completed D to JH rearrangement and are actively rearranging the VH to DJH 
gene segments. Pro-B cells also express terminal deoxynucleotidyl transferase (TdT) and 
two of the first identifiable B-cell markers, CD19 and CD45R (B220 in mice). CD19 and 
CD45R expression are maintained throughout B-cell development. Once VDJH 
rearrangement has been successfully completed the cells are pre-B cells. pre-B cells are 
actively undergoing V-J light chain rearrangements, and are characterized by expression 
of cytoplasmic mu (µ) heavy chain and surface expression of the pre-B cell receptor 
(Pre-BCR), which consists of µ heavy chain and the surrogate light chain (λ5 and VpreB). 
Once successful light chain rearrangement has occurred the cells have become immature 
B-cells and express surface IgM. 
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ce productive VDJH rearrangement has occurred, cells begin to express cytoplasmic µ 
heavy chains, most of which are retained in the endoplasmic reticulum (ER). However, 
some µ heavy chains associate with the ΨLC, Igα and Igβ to form a stable complex 
known as the pre-B cell receptor (pre-BCR). At this point the pro-B cell has transitioned 
from the pro-B cell stage to the pre-B cell stage of B-cell development (18). Surface 
expression of the pre-BCR is required for allelic exclusion of heavy chain gene 
expression (i.e. shutting down of rearrangement on the second chromosome) (19), and is 
absolutely required for pre-B cell progression (18). Ligand-independent oligomerization 
of the pre-BCR is the likely mechanism of proliferative stimulus for the expansion of 
pre-B cells with functional heavy chain rearrangements (11). However, some potential 
pre-BCR ligands that promote proliferation have been described (20,21). 
During the pre-B cell stage of development, cells are also actively undergoing 
rearrangements of the V and JL light chain loci, beginning with one of the two kappa light 
chain genes. If the rearrangement does not produce a functional kappa light chain, the 
cell will rearrange the second kappa light chain gene. If the kappa light chain 
rearrangement is successful the B-cell will make an Ig with a kappa light chain. If the 
kappa chain rearrangements are unsuccessful, the cell will attempt to rearrange the 
lambda light chain genes in succession until a functional rearrangement has occurred. As 
with heavy chain rearrangements, light chain rearrangements are also mediated by 
RAG-1 and RAG-2. Cells that fail to complete functional rearrangements of either the 
heavy or light chain loci will undergo apoptosis. Once a successful VJL rearrangement 
has occurred, a complete IgM molecule is expressed on the cell surface, and the cell is 
then defined as an immature B-cell. 
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Immature B-cells that have successfully expressed IgM on their surface are 
subject to both negative and positive selection via signals received through the antigen 
receptor. B-cells that express receptors that recognize auto-antigen, or self-reactive 
B-cells, undergo negative selection and have four possible fates: production of a new 
BCR by receptor editing, ignorance, anergy, or deletion (apoptosis) (13). If an immature 
B-cell expresses a receptor that recognizes self-antigen the cell is stimulated to commit 
apoptosis (deletion) or re-express RAG-1 and RAG-2 to undergo another round of 
receptor rearrangement (receptor editing) (22). Immunological ignorance of B-cells is the 
coexistence of self-reactive B-cells and their auto-antigen without any immunological 
response. This process results from 1) very low concentrations of self-antigen or 2) 
B-cells with low affinity to highly abundant self-antigen (23). Anergy occurs when an 
autoreactive B-cell binds to self-antigen in the periphery, this results in a reduction in 
surface IgM expression and cellular inactivation (23). The differential induction of 
ignorance, anergy and deletion, in that order, are directly proportional to the degree of 
receptor/self-antigen activation (23). These mechanisms prevent the development of 
autoimmunity. Non-self-reactive B-cells migrate into the periphery to secondary 
lymphoid organs where they undergo antigen specific positive selection (see GC 
reaction).   
1.1.2 The Bone Marrow Microenvironment 
 An important aspect of B-cell development is the site where it takes place. During 
embryogenesis, hematopoiesis occurs in the fetal liver and BM, but as we age, 
hematopoiesis becomes restricted to the BM microenvironment (24). The ability of HSC 
to self-renew and differentiate is critical for tissue homeostasis. If differentiation were to 
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overwhelm self-renewal then the HSC compartment would become depleted. Conversely, 
if HSC self-renewal occurred excessively at the expense of the mature compartments then 
leukemia would likely develop. This balance between self-renewal and differentiation is 
tightly controlled by the stem cell niche within the BM microenvironment (25). An 
important function of the stem cell niche, therefore, is to regulate the balance between 
asymmetric/symmetric stem cell division. 
The BM microenvironment is a spongy extracellular matrix containing fibronectin, 
collagen, laminin, and other proteoglycans that provide a scaffolding where stromal cells, 
such as osteoblasts, fibroblasts, endothelial cells, reticular cells, dendritic cells, or 
macrophages interact with different developing blood cells (25). Besides physical 
interactions, stromal cells also provide essential cytokines and growth factors required for 
proper development of B lineage cells. These factors are also absolutely required for the 
proper development and maintenance of the B-cell pool (25). For example, in mice, the 
cytokine IL-7 is required for B-cell development; without it cells become arrested at the 
Pro-B cell stage of development (26). In humans, the cytokine(s) that promote B-cell 
development are not quite as well understood (11). However, a common characteristic of 
leukemic disease is that transformed blood cells often lose stromal cell/growth factor 
dependency, leading to uncontrolled proliferation. This effect results in overcrowding of 
the BM microenvironment and disruption of normal blood cell development. 
1.1.4 B-Cell Disorders 
B-cell disorders are divided into two categories, 1) defects of Ig production 
(immunodeficiencies) and 2) excessive/uncontrolled proliferation (leukemias/lymphomas) 
(27). Rare defects in Ig production include X-linked agammaglobulinemia (XLA), 
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resulting from a mutation of the Bruton’s tyrosine kinase (BTK) gene, which leads to 
developmental arrest at the pro-B cell stage (28) and hyper-IgM syndrome, which results 
from a mutation in the CD40 ligand (CD40LG) gene leading to a loss of class switching 
and overproduction of IgM (29). Both of these diseases are inherited on the X 
chromosome and, therefore, only affect males. However, acquired disorders in Ig 
production are far more common than inherited genetic mutations.   
Leukemias corresponding to all stages of B-cell development have been found in 
humans, from the earliest stages to the terminally differentiated plasma cells. Acute 
B-cell leukemias occur at the earliest stages of B-cell development and involve the 
developmental arrest and uncontrolled proliferation of pro- and pre-B cells. Chronic 
B-cell leukemias involve immature, mature, or activated B-cells; multiple myelomas 
represent malignant outgrowths of plasma cells. Approximately 80% of all acute 
lymphocytic leukemias (ALL) are of the B-cell lineage (30), discussed in greater detail 
below.   
1.2 Leukemia: An Overview 
Leukemia, which literally means “white blood” in Greek, is an acute or chronic 
disease of the blood and blood-forming organs that originates in the BM and is 
characterized by an abnormal increase in the number of white blood cells in the tissues of 
the body. Abnormal increases in the number of white blood cells in the BM prevent 
normal blood cell development resulting in symptoms of anemia, fatigue, excess bleeding 
and infections. Each type of leukemia is categorized based on the white blood cell type 
that is predominately involved. In 2009 approximately 140,000 individuals in the United 
States will be diagnosed with leukemia or the leukemia-related diseases, lymphoma or 
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multiple myeloma (MM), and it is estimated that these diseases combined will account 
for approximately 53,000 deaths in the United States this year (Source: Surveillance, 
Epidemiology and End Results (SEER) Program 1975-2005, National Cancer Institute, 
2008).  
1.2.1 Causes and Risk Factors  
 Leukemias result from alterations in DNA resulting in the activation of oncogenes, 
the repression of tumor suppressor genes, or the generation of novel proteins with unique 
functions. The exact cause of these mutations is not well understood, but there is strong 
evidence supporting four likely causes. These include exposure to moderate to high doses 
of ionizing radiation, chemical exposure, viral infection, and genetic predisposition.  
Ionizing radiation. Humans are constantly exposed to relatively low amounts of 
ionizing radiation (without harm) from naturally occurring radionuclides in the ground, in 
building materials, and in foods. However, exposure to moderate to high levels of 
ionizing radiation can cause cancer. Leukemias are especially sensitive to induction from 
exposure to moderate to high levels of radiation. The first evidence of this property came 
from studies of the Japanese survivors of the atomic bombings of Hiroshima and 
Nagasaki (31). Indeed, there was a one hundred-fold increase in the incidence of 
leukemia five years following exposure to atomic radiation compared with the unexposed 
population (32). Most leukemias were in excess and were especially pronounced at young 
ages following exposure, with the exception of chronic lymphoid leukemia (CLL), which 
is rare in the Japanese population (33).  
Chemicals exposure. Exposure to certain chemicals as the result of 
indoor/outdoor air pollution, or occupational exposure, is also associated with an 
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increased risk of leukemia. Use of some insecticides and pesticides on interior and 
exterior plants, in particular frequent prenatal use, is associated with increased risk of 
leukemia (34). Furthermore, there is an increased risk of leukemia and lymphoma caused 
by exposure to volatile organic compounds such as benzene and 1,3-butadiene (35). 
Leukemias can also occur as the result of radiation therapy or chemotherapy for the 
treatment of primary tumors. These leukemias are referred to as secondary leukemias. 
Chemotherapeutic agents associated with secondary leukemias include: alkylating agents, 
topoisomerase inhibitors, or immunosuppressive agents such as azathioprine (36). 
Viruses. Certain viruses can also cause leukemia. For example, Epstein-Barr 
virus (EBV) has been linked to the development of both Hodgkin’s disease (HD) and 
Non-Hodgkin’s lymphoma (NHL) (35). Human T-cell leukemia virus type 1 (HTLV-1) is 
associated with adult T-cell leukemia, and the human immunodeficiency virus (HIV) 
with B-cell lymphomas (35).  
Genetic predisposition. Genetic predisposition plays a role in the risk for 
developing leukemia. Although only accounting for a small number of all leukemias, 
certain inherited diseases are responsible for an increased risk of developing leukemia. 
The diseases Fanconi anemia, Bloom syndrome, ataxia telangiectasia, Down syndrome, 
Shwachman syndrome, and neurofibromatosis are all associated with an increased risk of 
leukemia (37). These diseases are characterized by defects in DNA repair mechanisms, 
aneuploidy and chromosomal abnormalities. Other studies suggest that there is a 
increased risk of leukemia in children with siblings who develop leukemia (38,39). 
Finally, leukemia occurs more frequently in white individuals of European descent than 
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any other race or ethnicity, suggesting a genetic component to the disease in this 
population (37).  
1.2.2 Classifications 
Leukemias are grouped into four broad categories: acute lymphocytic (ALL), 
chronic lymphocytic (CLL), acute myelogenous (AML), and chronic myelogenous 
(CML). Acute leukemias are characterized by a rapid onset and occur primarily in 
children and young adults. Subtyping of the various forms of acute leukemia are done 
according to the French-American-British (FAB) or the World Health Organization 
(WHO) classification systems. Leukemias are classified under either system based on the 
type of cell from which the leukemia developed, cellular cytogenetics and phenotyping to 
determine the degree of cellular maturity. Symptoms of acute leukemia will often appear 
suddenly and, based on the nature of the disease, aggressive treatments are generally 
required. Treatment strategies are tailored to the specific type of white blood cell 
involved.  
Chronic leukemias are not at all common in children, occurring chiefly in older 
individuals. Chronic leukemias are characterized by a much slower progression, which 
can vary greatly from patient to patient. CML is divided into three phases; chronic phase 
(CP), accelerated phase (AP), and blastic phase (BP) (40). If left untreated CP lasts 2 – 5 
years; AP can last up to a year; and BP lasts 3 – 6 months and is fatal (40). CLL is staged 
clinically based on the schemes proposed by Rai et al. (41), and Binet et al.(42); low-risk, 
intermediate-risk, and high-risk or stages A, B, and C, respectively (41-43). For both 
schemes, anemia and platelet counts < 100 × 109/L are considered end stage CLL. The 
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treatments for both CLL and CML are dependent on the clinical stage and progression of 
disease. 
1.2.3  Childhood Leukemias  
In vertebrates, hematopoiesis is extremely active during fetal development as well 
as in the first few years of life; therefore, it is not surprising that leukemia is the most 
common childhood malignancy. In fact, although adults are diagnosed with leukemia 
about 10 times more frequently than children, leukemia is the number one disease of 
children (0 – 14 years) and accounts for 32.6% of all childhood cancers (Source: Cancer 
Facts and Figures 2007, American Cancer Society). Additionally, exceeded only by 
accidents, cancer is the second leading cause of death in children. Approximately one 
third of all childhood deaths result from leukemia (Source: Cancer Facts and Figures 
2007, American Cancer Society). In the United States approximately 2,000 children are 
diagnosed with ALL each year, approximately 500 children are diagnosed with AML, 
and less than 100 are diagnosed with CML (44). Although CLL is the most common of 
leukemias diagnosed in adults, it is rarely diagnosed in children (44). 
1.2.4 Treatment Options  
There are numerous chemotherapeutic agents with differing modes of action 
available for the treatment of cancer. There are compounds that interfere with DNA 
replication and gene expression, such as anti-metabolites and alkylating agents, others 
that inhibit cellular signaling pathways, such as tyrosine kinase inhibitors (TKI), and 
tumor cell specific monoclonal antibodies (mAb). Leukemia treatment regimens are 
tailored to the type of leukemia that a patient has, as certain treatments may be highly 
effective for one type of leukemia and not at all effective for another (Table 1). The over- 
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Table 1. Common chemotherapeutic drugs used to treat leukemia   
       
Drug  Type  Mechanism  Disease 
       
Vincristine  Mitotic Inhibitor  Disrupts microtubules, arrests 
mitosis in metaphase 
 ND, NHL, ALL 
Anthracyclines 
(Daunorubicin Doxorubicin) 
 Alkylating Agents  Intercalates into DNA, inhibits 
replication 
 ALL, AML, CLL 
Cyclophosphamide  Alkylating Agent  Forms DNA intrastrand 
crosslinks, inhibits replication 
 AML, CLL, 
Childhood-ALL, HD, 
MM 
ATRA (all-trans retinoic acid) 
 
 Retinoid  Induces cellular differentiation  APML 
Imatinib  Tyrosine Kinase Inhibitor Inhibits pro-survival cellular 
signaling pathways 
 Ph+ CML, Ph+ALL 
Cladribine  Anti-metabolite  Purine analog, interferes with 
DNA processing 
 Hairy Cell Leukemia 
Fludarabine  Anti-metabolite  Purine analog, interferes with 
DNA synthesis 
 CLL 
Methotrexate  Anti-metabolite  Inhibits folate metabolism, 
blocks nucleoside synthesis 
 ALL, lymphomas 
Mercaptopurine  Anti-metabolite  Inhibits purine synthesis  ALL 
Cytarabine  Anti-metabolite  Cytosine analog, prevents 
DNA synthesis 
 ALL, AML, CML 
Asparaginase  Catalytic enzyme  Deprives leukemic cells of 
circulating asparagine 
 ALL 
Rituximab  Monoclonal Antibody Binds to CD20, induces 
apoptosis of CD20+ B cells 
 CLL, NHL 
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all goal of treatment for leukemia is complete remission, and significant progress has 
been made over the past several decades to achieve this aim. However, conventional 
chemotherapeutics are still not always 100% effective at eradicating disease.  
ALL. The greatest success story for treatment of leukemia is that for treatment of 
childhood ALL. Treatments for childhood ALL include: vincristine, steroids, 
anthracyclines, cyclophosphamide, asparaginase, methotrexate, mercaptopurine. The fine  
tuning of treatment schedules, dose-intensities, and delivery have increased the cure rate 
for pediatric ALL from approximately 30%, forty years, ago to 80% today (45). Using 
the same principle for the treatment of adult ALL, complete response (CR) rates or the 
disappearance of all signs of cancer are 80% to 90% today and cure rates are up to 40% (45). 
AML. The most effective strategy for treating AML for the last 30 years is known 
as the “3 + 7 regimen” and consists of intravenous daunorubicin for 3 days followed by 7 
days of continuous infusion with intravenous cytarabine (45). Presently, for patients with 
AML, the CR rate to daunorubicin and cytarabine is between 60% and 70% with a long 
term survival rate of 25% to 35% compared to 40 years ago when CR rates were between 
20% and 30%, and long term survival was rare (45).  
CML. Up to 95% of CML cases result from a reciprocal chromosomal 
translocation that fuses the long arm of chromosome 9 to the long arm of chromosome 22, 
known as the Philadelphia chromosome (Ph+) because it was first discovered and 
described by two scientists in Philadelphia, PA (46,47). This translocation results in the 
fusion of the break point cluster region (Bcr) gene with the Abelson (c-abl) gene, which 
encodes a non-receptor tyrosine kinase involved in cellular signaling. As a result, the 
Bcr-Abl chimeric protein has constitutive tyrosine kinase activity resulting in the 
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activation of down stream signaling pathways that promote leukemic cell survival and 
proliferation (46). CML used to be considered a poor prognosis leukemia until the 
discovery of imatinib mesylate (48,49). Imatinib mesylate (Gleevec ®/STI571/ Novartis 
compound CGP 57148) is a tyrosine kinase inhibitor that has high affinity for the Abl 
kinase domain, while being essentially inactive against most other tyrosine kinases with 
the exception of the platelet-derived growth factor (PDGF) receptor and c-kit (50). Since 
the introduction of imatinib for treatment of CML, the CML-specific annual mortality 
rate has dropped from between 10% and 20% to 1% today (45). Resistance to imatinib 
occurs in approximately 3% to 4% of CML patients and 50% are the result of mutations 
in the Abl kinase domain (45). The Bcr-Abl fusion is also the most frequent genetic 
aberration in adult ALL and is found in 20% – 30% of patients. Imatinib is also highly 
effective for the treatment of non-resistant, Ph+, adult ALL, and the prognosis for these 
patients is excellent.(51)  
CLL. The treatment of choice today for CLL in fludarabine. Fludarabine is an 
adenosine nucleoside analog that inhibits DNA polymerase (52). Before fludarabine, 
patients were treated with vincristine, steroids, cyclophosphamide, and anthracyclines. 
However, fludarabine has been demonstrated to be superior to these earlier treatments for 
CLL (53,54). Treatment with both fludarabine and cyclophosphamide has been shown to 
increase CR rates for CLL patients greater than fludarabine alone (55). More recently, in 
a study at the M. D. Anderson Cancer Center at the University of Texas, Houston, CLL 
patients were treated with a combination of fludarabine, cyclophosphamide and rituximab. 
Rituximab is a monoclonal antibody that recognizes CD20, a B-cell specific antigen that 
is expressed throughout B cell development beginning at the early pre-B cell stage (56). 
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Of the 300 patients in this study, 72 % had CR with an estimated 5 year survival of 79% 
(57). Other chemoimmunotherapy treatments still under investigation include fludarabine 
plus alemtuzumab, a CD52 specific mAb; or lumiliximide, a CD23 specific mAb (45).  
Leukemia subsets. There are specific subsets of leukemia for which individual, 
highly effective treatments have been discovered. Acute promyelocytic leukemia (APL) 
is a subtype of AML characterized by a unique chromosomal translocation resulting in 
the fusion of the retinoic acid receptor alpha (RARα) encoding gene and the 
promyelocytic leukemia (PML) encoding gene (58). APL may be the most severe form of 
acute leukemia, with a fatal course of only a few weeks. Initially, chemotherapy for APL 
consisted of anthracyclines and cytarabine with CR rates of approximately 80% (58). 
However, the duration of remission was only 11 to 25 months with cures rates between 
35% to 45% (58). The discovery of the anti-APL activity of all-trans retinoic acid 
(ATRA) and arsenic trioxide (ATO) was a major breakthrough for the treatment of APL. 
The mechanism of ATO-induced APL leukemic cell death is not entirely understood. 
However, ATRA, which was first used clinically in 1985 (59), strongly induces 
promyelocytes to terminally differentiate (58). Today, combination therapy of ATRA and 
ATO have improved CR rates to 90% and cure rates to 70% to 85% (45). 
Hairy cell leukemia (HCL) is an uncommon form of CLL occurring primarily in 
older males. The name comes from the appearance of the cells under the microscope; 
cells appear to be covered with tiny hairs. The prognosis for HCL prior to the discovery 
of effective therapies was unfavorable. The mean survival for patients with HCL was 5 
years (45). Since the advent of Cladribine (2-Chlorodeoxyadenosine; CDA), the 5 to 10 
year survival of patients with HCL has increased to 90% (60). Today, HCL is associated 
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with excellent long-term outcome after 1 or 2, 5-day courses of a relatively nontoxic 
chemotherapy with Cladrabine (45). 
1.3  Molecular Genetics of Leukemia  
 Unlike solid tumors, which are vastly heterogeneous in nature, leukemias are 
generally regarded as clonal malignancies characterized by the accumulation of somatic 
mutations in cellular DNA (61). These mutations lead to an arrest in differentiation and 
confer a proliferative and/or survival advantage for the cells affected. With the exception 
of CLL, chromosomal translocations account for the vast majority of leukemias (61-63). 
In fact, nonrandom chromosomal translocations account for approximately 70% of all 
acute leukemias (63). Chromosomal translocations that have been observed in leukemia 
can be grouped into several categories, including: translocations that activate tyrosine 
kinases, those that affect the function of transcription factors, and those that regulate the 
cells’ transcriptional machinery (61).  
 The most commonly occurring translocation leading to the activation of a tyrosine 
kinase is the Bcr-Abl fusion. As mentioned, approximately 95% of CML cases result 
from the reciprocal chromosomal translocation that fuses chromosome 9 to chromosome 
22, the Philadelphia chromosome (46,47). This translocation results in expression of a 
Bcr-Abl chimeric protein that has constitutive tyrosine kinase activity which alters 
signaling pathways that control the proliferation, survival, and self renewal of 
hematopoietic cells (46). In addition, 20% – 30% of adult ALL result from this same 
translocation (30).  
The most frequent targets of chromosomal translocations in acute leukemia are 
genes encoding transcription factors. There are two main mechanisms by which 
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chromosomal translocations lead to the activation of transcription factors. The first 
mechanism involves a transcription factor-encoding gene translocated to the vicinity of  
a constitutively active promoter or enhancer element, such as those of the TCR or Ig 
encoding genes. The second mechanism involves two genes encoding transcription 
factors being incorporated into a single “fusion” gene generating a chimeric protein with 
altered function (63). Chimeric transcription factors activate transcriptional cascades that 
modify the normal pattern of gene expression within the cell.  
Genes involved in chromosomal translocations in acute leukemia are highly 
conserved evolutionarily and are often directly or indirectly involved in controlling the 
earliest stages of embryonic development (63,64).  For example, the chromosomal 
translocation t(12;21) fuses the 5’ portion of the TEL gene, a member of the ETS family 
of transcription factors, with nearly the entire  coding region of the AML1 gene, a 
runt-related transcription factor and regulator of HSC commitment (65). This fusion 
results in the transcriptional silencing, instead of activation, of AML1 target genes due to 
transcriptional repression domains retained in the TEL protein (66). This results in the 
altered self renewal and differentiation capacity of HSCs (30,65). Furthermore, members 
of the HOX gene family (described below) may lie downstream of AML1 (67). HOX 
genes encode a family of transcription factors that play a critical role in embryogenesis 
and hematopoiesis. 
The gene most frequently involved in chromosomal translocations in acute 
leukemia is the mixed lineage leukemia (MLL; a.k.a. HRX or ALL1) gene (63). To date, 
greater than 51 chromosomal translocation partners for MLL have been identified in acute 
leukemia (68). In decreasing frequency, the most frequent MLL fusion partners are AF4, 
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AF9, ENL, AF6, ELL, and AF10 (69). Approximately 80% of infant pre-B cell ALL are 
associated with MLL translocations (70,71). Leukemias bearing MLL translocations are 
associated with a poor prognosis. Furthermore, MLL translocations are found in therapy 
induced AML (t-AML) in infants, children and adults (68). In leukemic cells downstream 
targets of MLL fusion proteins have not been entirely identified (72). However, leukemias 
bearing MLL translocations are profoundly associated with overexpression of specific 
members of the HOX gene family, including HoxA7 and HoxA9 (68). 
1.4  Human HOX Gene Family 
Hematopoiesis is a intricate process regulated by the expression of multiple 
transcription factors that are either activated or inhibited as hematopoiesis proceeds. 
Deregulation of transcription factor expression and activity is believed to be required for 
malignant transformation (63). A specific set of evolutionarily conserved homeodomain 
containing genes, HOX genes, are responsible for encoding a family of transcription 
factors involved in early development that control pattern formation during 
embryogenesis.  The HOX gene family contains conserved sequences of 183 
nucleotides that encode a 61 amino-acid, helix-turn-helix, DNA-binding motif. The core 
homeodomain DNA-binding motif recognizes DNA sequences ranging from TGAT to 
TAAT to TTAT and TTAC (73). 
 In mammals, there are 39 different class I HOX genes organized into four 
individual clusters (HOXA, B, C, and D), covering distances of approximately 150 – 200 
kb, located on four separate chromosomes (Fig. 3).  These clusters may be further 
grouped into subclasses based on their primary sequence into 13 paralog groups within 
each individual cluster. Each HOX gene has a polyadenylation site, promoter, and a high- 
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Figure 3: The Human HOX Genes. There are 39 human HOX genes organized into 
four clusters (A – D) located on four separate chromosomes. The clusters are further 
divided into subclasses based on there primary sequence homology into 13 paralog 
groups. During embryogenesis the 3’ HOX genes are expressed early in the anterior 
region of the embryo and the 5’ HOX genes are expressed late in the posterior region of 
the developing embryo. The colored fields represent the anterior most limits of 
expression during embryogenesis i.e. HoxA1 is only expressed at the most anterior region 
of the developing embryo. Moving from the posterior to the anterior, expression levels 
fade and the boundaries of each expression domain overlap. Despite a role in 
embryogenesis and hematopoiesis, few HOX downstream targets have been identified.  
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ly conserved order within the clusters (74). A critical role of the HOX transcription 
factors is the tight control and maintenance of HSC differentiation and proliferation.  
1.4.1  Regulation of HOX Genes 
Several HOX genes from the A, B, and C clusters are expressed in distinct 
patterns during hematopoiesis and embryogenesis (75). HOX genes exhibit a temporal 
spatial pattern of expression during both hematopoiesis and embryogenesis. In the 
embryo, the 3’ HOX genes are expressed early in the anterior region of the developing 
embryo and the 5’ HOX genes are expressed in the posterior region of the developing 
embryo late during embryogenesis. HOX genes are determinants of cell fate. The 
differentiation and stage-specific expression of each HOX gene programs cells to the 
appropriate developmental stage before advancing to the next stage of differentiation. 
During hematopoiesis, the 5’ HOX genes are highly expressed in primitive 
stem/progenitor cells, and down-regulated as cells become committed to different lineage 
specific programs (76). Several mechanisms have been identified for the regulation of 
HOX gene expression. The identification of a TAAT retinoic acid response element 
sequence (RARE) in upstream promoter regions, common amongst HOX genes, allows 
for the binding of HOX proteins and subsequent activation through positive feedback 
(77). The genes involved in the maintenance of HOX gene expression in Drosophila 
melanogaster include the polycomb (Pc-G) gene, which encodes a repressor of HOX 
gene expression, and trithorax (Trx-G) gene, which encodes a protein responsible for the 
maintenance of HOX gene expression. Following the discovery of these genes in 
Drosophila, they were also identified in mammals. In humans, the MLL gene represents 
the human homologue of the Trx-G gene (77). Chromosomal translocations involving the 
30 
MLL gene almost invariably result in deregulation of HOX gene expression, and have 
been described in a number of human leukemias (75). 
1.4.2  HOX in Normal and Malignant Hematopoiesis 
Commitment and differentiation of HSCs is under precise genetic control, and 
there is evidence that HOX genes play a significant role in this regulatory process (75). 
Genes of the HOXA and HOXB clusters are preferentially expressed in CD34+ human 
BM cells. Additional analysis of CD34+ BM cells revealed two distinctive patterns of 
HOX gene expression in different sub-populations of CD34+ cells. HOXA and HOXB 
genes located at the 3’ ends of the clusters are expressed invariantly in all CD34+ cells 
such as CLPs or pro-B cells. However, HOXA and HOXB genes located at the 5’ ends of 
the clusters are expressed at high levels only in the most primitive sub-populations of 
CD34+ cells (76). 
Several experiments have been performed to illustrate the importance of HOX 
gene expression and regulation during hematopoiesis. For example, HoxA5 
overexpression in human BM leads to an increased number of myeloid cells and lower 
numbers of erythroid progenitors (78). Conversely, limited expression of HoxA5 in BM 
cells results in higher numbers of erythroid progenitors and lower numbers of 
myelomonocytic cells (79). Overexpression of HoxA10 profoundly perturbs 
differentiation of CD34+ hematopoietic cells into megakaryocytes, inhibits B-cell 
development, enhances proliferation of hematopoietic progenitors, and ultimately may 
induce AML (80). Disruption of HoxB6 expression leads to expansion of erythroid 
progenitors but a lack of erythroid differentiation (75). These examples illustrate how 
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deregulation of HOX gene expression can have severe effects on normal hematopoiesis, 
and underscore the importance of maintaining proper HOX gene expression. 
Not surprisingly, deregulation of HOX gene expression, as a result of genetic 
mutation, is most highly associated with leukemia. The involvement of abnormal HOX 
gene expression in the development of leukemia was first identified in the WEHI-3 
myeloid leukemic cell line. A block in the differentiation of myeloid leukemic cells 
results from a constitutively active HoxB8 gene due to a proviral insertion (81). 
Overexpression of IL-3 in this cell line led to the generation of IL-3 dependent 
myelomonocytic, megakaryocytes, and mast cells in vitro, and leukemia in vivo. The 
synergistic effects of the expression of both genes is highly transforming (81). More 
evidence demonstrating the involvement of aberrant HOX gene expression in leukemia 
came from the work of Nakamura and colleagues (82). Retroviral activation of HoxA7 
and HoxA9 along with a retrovirally activated Meis1 gene in BXH-2 mice resulted in the 
development of myeloid leukemia. Coexpression of HoxA9, HoxA7 and Meis1 has been 
observed in human AML (83). Furthermore, overexpression of HoxA9 alone in murine 
BM results in AML, and coexpression of HoxA9 and Meis1b in mice, leads to the 
accelerated onset of leukemia compared to mice overexpressing HoxA9 alone, suggesting 
that cofactors of HOX may assist in the acceleration of the onset of leukemic 
transformation (83,84). Murine bone marrow transduction experiments using retroviral 
vectors provide a useful model for the study of human leukemia, and although it has not 
been shown for all HOX genes, overexpression of specific HOX genes has been shown to 
perturb normal hematopoiesis. 
1.4.3  HOXA9 in Hematopoiesis and Leukemogenesis  
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Like other 5’ members of the HOXA gene cluster, HoxA9 is strongly expressed in 
the most primitive CD34+ population of hematopoietic precursors and is subsequently 
downregulated as cells differentiate into the various sub-populations of blood cell types. 
To determine the role of HoxA9 in hematopoiesis, Lawrence et al. used HoxA9 knockout 
mice to examine the physiological effects that this mutation would have on hematopoietic 
cell development (85). Mice bearing the HoxA9 mutation were physically similar to their 
wild-type littermates, with respect to health and weight, and were not predisposed to 
infection or leukemia following a year of observation (85). However, HoxA9-/- mice 
exhibited the most severe hematopoietic defects with a 33% reduction in the numbers of 
granulocytes, a 40% reduction in the numbers of B220+ B-cells, and a 35% reduction in 
the number of CD3+ T-cells. The homozygous HoxA9 knockout mice showed a percent 
distribution of myeloid/erythroid cell types similar to wild type mice; however, there was 
a global two-fold reduction in the total number of cell types in the mutant due to a 
decrease in the number of progenitor cells in the BM (85). As a result of the overall 
decrease in the number of progenitor cells, the homozygous HoxA9 mutant mice had 
smaller spleens and thymuses compared to wild type animals (85). These results 
demonstrate that HoxA9 plays a key role during the early stages of normal 
hematopoiesis.   
The transforming effects of HoxA9 are enhanced by other oncogenic factors, 
including overexpression of Meis1a and expression of the E2A-Pbx1a fusion protein. The 
Sauvageau group showed that primary BM cells engineered to overexpress HoxA9 
invariably led to the development AML within 3 to 10 months when transplanted into 
syngeneic mice (74,84,86). Moreover, when HoxA9 was overexpressed in primary BM 
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cells along with the HOX cofactor Meis1a or the E2A-Pbx1a fusion oncoprotein, they 
develop into AML when transplanted into syngeneic mice with a significantly shorter 
latency period than cells overexpressing HoxA9 or Meis1a alone (84,87). This same 
group demonstrated that overexpression of HoxA9 in more mature lymphoid cells 
partially blocked B lymphopoiesis at the pre-B-cell stage but had no detectable effect on 
T lymphoid development (86). Based on the seemingly central role that HoxA9 plays in 
normal hematopoiesis and leukemogenesis, it is not surprising that HoxA9 is the most 
frequently deregulated HOX gene in acute leukemia (88), and overexpression of HoxA9 
is the single most highly correlated factor with poor prognosis for patients with AML 
(89). 
Despite overwhelming evidence for the critical role that HoxA9 plays in normal 
and malignant hematopoiesis, very few direct downstream targets of HoxA9 have been 
empirically defined. These include: Pim-1 (90,91), c-Myb (92), gp91Phox (93), and some 
members of the Wnt gene family (94). Furthermore, an association between HoxA9 
activity and growth receptor signaling has not been previously described.  
1.5  Insulin-Like Growth Factor-1 Receptor  
The insulin-like growth factor-1 receptor (IGF-1R) is a ubiquitous transmembrane 
receptor tyrosine kinase that is essential for the development and growth of normal 
tissues (Fig. 4). Signaling through IGF-1R stimulates cell proliferation and differentiation, 
changes in cell size, and can protect cells from apoptosis. IGF-1R is primarily the 
receptor for IGF-1, but can also bind IGF-2 and insulin, although the affinity for insulin 
is three orders of magnitude lower than that for IGF-1 or IGF-2 (95). IGF-1 is a growth 
factor produced primarily by liver and stromal cells of the BM microenvironment. IGF-1  
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Figure 4: The Insulin-like growth factor-1 receptor (IGF-1R). IGF-1R is a 
heterotetramer receptor tyrosine kinase consisting of two extracellular alpha chains, 
containing the ligand binding domain, and two intracellular beta chains, containing the 
catalytic domains. The half-life of the ligand, IGF-1, is prolonged in the plasma by IGF-1 
binding protein 1. Binding of IGF-1 results in autophosphorylation of the beta subunits of 
the receptor. This results in the recruitment and subsequent activation of the auxiliary 
signaling proteins, insulin receptor substrates 1 – 4 (IRS-1–4) and Shc. Phosphorylation 
of IRS-1 results in activation of the PI3K/Akt pathway leading to signals promoting cell 
survival and protection from apoptosis. IRS-1 along with Shc can also induce signaling 
through the MAPK/ERK pathway  through activation of Ras, leading to increased 
cellular proliferation. Both pathways converge to promote tumor growth.   
 
 
 
 
 
 
 
 
 
 
 
 
3
5
 
 
PP
Ras
GTP GDP
Raf
MEK
MAPK
IR
S-
1 -
4
P
P
P
Sos
Shc
Sos
Grb2
Grb2
Akt
PI3K
IGF-1R
IGF-1/2
Cytoplasm


Proliferation Cell Survival/Apoptotic Resistance
Tumor Progression
IGF-1/2IGFBP1
36 
is a potent mitogenic and anti-apoptotic molecule involved in the regulation of cell 
proliferation in renewing epithelial cell populations of organs including: breast, prostate, 
colon, and lung (95).  
IGF-1 is a 6 – 8 kDa protein found in serum between 10 and 100 nmol/l and 
functions to stimulate a variety of metabolic processes (89). Endocrine expression of 
IGF-1 from the liver and BM is regulated by growth hormone (GH). Recent evidence 
also suggests that other tissue types are also capable of expressing IGF-1 (89). Thus, 
IGF-1 ligand is subjected to endocrine and paracrine regulation, as well as autocrine 
regulation in the case of many types of tumor cells (96).  
The IGF-1 receptor is a pre-formed hetero-tetramer containing two alpha and two 
beta chains covalently linked by disulfide bonds. The receptor subunits are synthesized as 
part of a single polypeptide chain of 180 kD, which is proteolytically processed into 
alpha (130 kD) and beta (95 kD) subunits (97). The alpha chain is the extracellular 
domain and contains the site for ligand binding. The beta chain possesses the 
transmembrane domain, and the tyrosine kinase catalytic domain. Upon binding of IGF-1, 
the IGF-1R undergoes autophosphorylation at conserved tyrosine residues within the 
catalytic domain of the beta chain. Subsequent phosphorylation of additional tyrosine 
residues within the beta chain provides docking sites for molecules critical to the 
intracellular signaling, including the insulin receptor substrates (IRS) 1 – 4 and Shc. 
These substrates initiate phosphorylation cascades that transmit the IGF-1R signal (98).  
The principle pathways for transduction of the IGF-1 signal are mitogen-activated 
protein kinase/extra cellular receptor kinase (MAPK/ERK) and phosphatidylinositol 
3-kinase/Akt (PI3K/Akt) pathways (99). Phosphorylated IRS-1 activates PI3K, leading to 
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activation of Akt. Phosphorylated Akt enhances protein synthesis through mTOR and 
promotes cell survival. PI3K can also recruit Grb2/SOS by phosphorylated IRS-1 or Shc, 
which leads to the recruitment of Ras, and activation of the MAPK/ERK pathway. The 
MAPK/ERK pathway is primarily responsible for the mitogenic signal elicited following 
stimulation by IGF-1, and PI3K/Akt is responsible for the IGF-1R–dependent induction 
of anti-apoptotic or survival processes (96). Some studies suggest that signaling through 
the PI3K/Akt pathway can enhance and/or synergize with MAPK/ERK signaling, 
providing a more robust pro-survival signal (100). Thus, signaling through IGF-1R can 
promote both cellular proliferation and apoptotic resistance through two different cellular 
signaling pathways. 
The caspase family of cysteine proteases plays a pivotal role in the execution of 
apoptosis (101). Stress-induced mitochondrial membrane instability results in the release 
of cytochrome C, which causes activation of the caspase cascade through caspase 
cleavage. This effect leads to collapse of the cellular infrastructure (101). The PARP 
protein is the best characterized substrate of caspase cleavage and PARP cleavage is 
often used as an indicator of apoptosis (102). IGF-1R signaling through PI3K/Akt can 
exert its anti-apoptotic effects through phosphorylation of the pro-apoptotic protein BAD 
(103,104). BAD influences the integrity of the mitochondrial membrane, and the release 
of cytochrome C, by associating with Bcl-2 and Bcl-xl, inhibiting their anti-apoptotic 
function (105). Phosphorylation of BAD by Akt blocks the pro-apoptotic activity of BAD 
(106). However, BAD is also phosphorylated, and inhibited, by the anti-apoptotic kinase 
Pim-1, a direct transcriptional target of HoxA9 (91). 
1.5.1 IGF-1R and Cancer 
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Overexpression of growth factors and/or their receptors is a common event in 
many cancers, and it is therefore not surprising that many studies have implicated IGF-1R 
and its ligands in the development, maintenance, and progression of cancer (95). Early 
studies of the IGF-1R gene noted sequence homology between IGF-1R and tyrosine 
kinase oncogenes (97). Early studies also demonstrated that IGF-1 is mitogenic for breast 
cancer cells in vitro (107). Later it was demonstrated that IGF-1R expression was present 
on many human cancers (108), and that IGF-1 can stimulate the growth of multiple 
human neoplasms (98,109). 
Overexpression of IGF-1, IGF-2, IGF-1R, or combinations thereof have been 
reported in glioblastomas, neuroblastomas, meningiomas (110), medulloblastomas (111), 
pancreatic carcinomas (112), and ovarian cancer (113). IGF-1R activity is also implicated 
in several solid tumors, such as those of the breast, prostate and colon, where aberrant 
HOX-gene expression has also been reported (114-116). Furthermore, multiple studies 
have demonstrated an increased risk of cancer associated with high levels of circulating 
serum IGF-1 (115-123). In fact, high serum levels of IGF-1 have been shown to correlate 
with childhood leukemia; an association between high infant birth weight and infant ALL 
that correlates with high levels of IGF-1, the so-called “big baby hypothesis” (124,125). 
In leukemia, studies have shown that autocrine signaling through IGF-1R 
promotes the growth of AML cells and inhibition of IGF-1R signaling in these cells 
results in the apoptosis (126). It was also reported by this group that chemoresistance of 
AML cells correlated with IGF-1 expression (126). In other studies signaling through 
IGF-1R has been reported to relieve leukemic cells of IL-3 dependency, and blocking 
IGF-1R signaling in these cells inhibited proliferation and induced apoptosis (127,128). 
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Additionally, one study demonstrated that proliferation of the pre-B ALL cell line, REH, 
could be inhibited in a dose-dependent manner by monoclonal antibodies against IGF-I 
and IGF-1R (129).  
The central role that the IGF-1R plays in promoting tumor survival and 
proliferation makes it an attractive target for cancer therapeutics. In 1989, the first 
evidence that an IGF-1R specific antibody (αIR3) could reduce tumor growth rate in 
animal models was demonstrated (130). Since then various strategies have been 
employed to inhibit IGF-1R expression and signaling both in vitro and in vivo. Among 
these strategies are: antisense oligonucleotides (131), antisense RNA (132,133), siRNA 
(134), triple helix-forming oligodeoxynucleotides (131), single chain antibodies (135), 
fully humanized monoclonal antibodies (136-138), and small molecule kinase inhibitors 
(139,140). Inhibitors of IGF-1R signaling are currently being used in clinical trials to 
treat solid tumors in humans. So far, the results have been promising and suggest that 
targeting IGF-1R in vivo may inhibit tumor growth and induce tumor cell death. 
Furthermore, the use of IGF-1R inhibitors along with other conventional therapies may 
increase the efficacy of treatment (141).   
1.6 Experimental Objectives 
1.6.1 Overview 
The goal of this proposed research project was to elucidate the molecular 
mechanisms that contribute to survival and proliferation of pre-B ALL cells as a result of 
deregulated HoxA9 expression. Deregulation of HoxA9 expression is highly associated 
with acute leukemia; however, the role that HoxA9 overexpression plays in promoting 
leukemic cell growth and survival is not well understood. The proposed experiments 
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were designed to test the hypothesis that HoxA9 overexpression promotes the growth and 
survival of acute leukemic cells through activation of specific downstream signaling 
pathways. Although tremendous improvements have been made in the treatment of ALL 
over the past few decades (45), conventional chemotherapy is not 100% effective in the 
treatment of leukemia. In fact, leukemias bearing MLL translocations are associated with 
a poor prognosis. Moreover, approximately 80% of infant pre-B cell ALL are associated 
with MLL translocations (70,71). These leukemias represent a major subgroup of ALL 
with a particularly poor prognosis and require innovative treatment strategies (70,71). 
Leukemias bearing translocations of the MLL gene are profoundly associated with 
overexpression of HOX genes, particularly HoxA9 (68). Furthermore, HoxA9 
overexpression also represents the single most highly correlated factor with treatment 
failure and poor prognosis for patients with AML. Therefore, identifying pathways 
altered by HoxA9 overexpression, which promote the survival and proliferation of acute 
leukemic cells, might provide valuable therapeutic targets for treatment of acute 
leukemia.  
1.6.2 System  
To determine how HoxA9 expression may contribute to the growth and survival 
of B-lineage acute leukemia, in vitro cell line models of pre-B cell ALL were utilized. 
Chiefly, the cell line that was used was the stromal cell-dependent pre-B ALL (CD10+, 
CD19+, pre-BCR+) cell line, BLIN-2 (B-Lineage-2). BLIN-2 cells were derived from 
cyropreserved BM cells from a pediatric patient with newly diagnosed pre-B cell ALL 
(142). The karyotype of this cell line is 46,XX,18,dic(9;20)(p11;q11.1) and it shares 
clonal identity with the patient’s original BM leukemic cells (142). BLIN-2 cells lack 
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HoxA9 expression and are absolutely dependent on stromal cell contact for survival and 
proliferation. As leukemic cells become more malignant they often lose dependency on 
growth factor/stromal cell support for survival and proliferation. Therefore, the BLIN-2 
model allows us to test effects of HoxA9 overexpression on promoting growth 
factor/stromal cell independent growth of leukemic pre-B cells in the context of the 
tumor microenvironment.  
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CHAPTER 2: Materials and Methods 
2.1 Cell Culture and Cell Lines  
BLIN-2 and BLIN-3 cells have been described previously (142-144). 
BLIN-2/MigR1 or BLIN-2/HoxA9:ER cells were generated by retroviral transduction, 
followed by fluorescence activated cell sorting (FACS) for stable retroviral clones. 
BLIN-2 and BLIN-3 cells were maintained on foreskin fibroblast stromal cell layers as 
previously described (142-144). BLIN-3 cultures were supplemented with 10 ng/ml IL-7 
(Peprotech, Rock Hill, NJ). BLIN-2 cells were maintained in serum free XVIVO-10 
(Lonza BioScience, Walkersville, MD) without phenol red. RS4;11 (145) and SEMK2 
(146) cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 
10% heat inactivated fetal calf serum, 100 U penicillin/ml, and 100 µg streptomycin/ml.   
2.1.1 Cell Growth and Proliferation 
Cell growth was evaluated via the MTT assay using CellTiter 96® reagent 
(Promega, Madison, WI). Briefly, 2 × 104 cells were washed 3 times in phenol red free 
XVIVO-10 medium and were seeded in triplicate into 96-well plates in phenol red free 
XVIVO-10 in the presence or absence of stromal cells. In some experiments cells were 
treated with 4HT (1 µM) (Sigma, St. Louis, MO), human recombinant IGF-1 (50 ng/ml) 
(Peprotech, Rocky Hill, NJ), AG1024 (1 µg/ml) (Calbiochem, La Jolla, CA)  and/or the 
A12 mAb (15 ug/ml), at the indicated times, 20 µl of CellTiter 96® labeling reagent 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl-2H-tetrazoli
um, and phenazine ethosulfate] was added to each well and incubated at 37°C for 3 hr. 
The absorbance was measured at 492 nm and is expressed as relative proliferation. 
Unless indicated otherwise, all experiments were performed in triplicate. 
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2.2 Retroviral Vectors 
The full length murine HoxA9 cDNA (87) (kind gift of G. Sauvageau, Institute 
for Research in Immunology and Cancer, Montreal, Canada) was fused in-frame with the 
hormone binding domain of the human estrogen receptor, and tagged with the 14 amino 
acid V5 epitope. The HoxA9:ER:V5 sequence was then cloned into the EcoRI and XhoI 
sites of the MigR1/IRES/GFP retroviral vector (147) to generate the HoxA9:ER 
construct.  
2.2.1 Retroviral Infection 
T75 flasks were coated with 0.1% gelatin for 1 hr at room temperature (RT). 6 × 
106 HEK-293 cells were plated in 10 ml of Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% heat inactivated fetal calf serum, 100 U penicillin/ml, 
and 100 µg streptomycin/ml. Cells were cultured overnight at 37°C. 20 pmol of the 
expression vector and 20 µg of pCL-Ampho (Imgenex, San Diego, CA) were added to 
1.5 ml of 0.25 M CaCl2. The mixture was added to 1.5 ml of 2 × HBS (50 mM HEPES, 
280 mM NaCl, and 1.5 mM Na2HPO4), pH 7.17 and incubated at RT for 30 min. The 
mixture was added to HEK-293 cell containing flasks and incubated at 37°C for 6 hr. 
Cells were then glycerol shocked with a 15% glycerol/phosphate buffered saline (PBS) 
solution, fresh DMEM was added and cells were incubated for 48 hr at 37°C prior 
harvesting of viral supernatant. Viral supernatant was filtered through a cellulose-acetate 
0.45 µm filter (Millipore, Billerica, MA) and used immediately for retroviral transduction. 
For retroviral transduction, BLIN-2 cells were plated at a density of 1 × 106 cells/well in 
6 well plates without stromal cell feeder layers in 1 ml of XVIVO-10 media, 4 µl of 
polybrene, and 1 ml of filtered viral supernatant per well. Following 6 hr incubation at 
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37°C, 3 ml of XVIVO-10 media was added to each well. Following 24 hr incubation at 
37°C, cells were transferred to flasks with stromal cell feeder layers and cultured for 48 
hr. Successfully transfected cells were FACS purified based on GFP expression. HoxA9 
expression was confirmed by western blot analysis. Transfected cells were maintained in 
phenol red free XVIVO-10 media in the presence of stromal cell layers.  
2.2.2 Flow Cytometry/Cell Sorting  
Following retroviral infection, cells that were successfully transduced were 
purified on the basis of GFP expression by fluorescence activated cell sorting (FACS) 
using a FACS Vantage instrument (Becton-Dickenson, Moutainview, CA). For analysis 
of GFP expression, 1 × 106 cells were collected and resuspended in 300 µl of FACS 
buffer (1 × PBS, 2.5% fetal calf serum, and 0.02 NaN3, pH 7.4) and analyzed using a 
FACSCalibur flow cytometer and CellQuest-Pro software. 
2.3 Western Blot  
Leukemic cells were lysed in ice cold RIPA buffer (10 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1 mM EDTA, 1 % NP-40, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 1 
mM Na3VO4, 1 mM EGTA, 10 mM NaF, 1 mM sodium pyrophosphate, and 0.1 mM 
β-glycerophosphate) for 30 min at 4°C. The lysates were centrifuged for 30 min at 20,000 
× g at 4°C. The supernatant was removed and the protein was quantitated using 
Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL). Twenty to 40 µg of 
protein per sample was electrophoresed on a 10 % SDS-polyacrylamide gel 
electrophoresis (PAGE) gel and then transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Millipore, Billerica, MA). The membranes were blocked with 5 % nonfat 
milk/TBST (50mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween-20) or 5 % bovine serum 
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albumin (BSA) /TBST. For some experiments, cytoplasmic and nuclear fractions were 
separated using the Pierce NE-PER Kit as per manufacture’s instruction. 
Membranes were incubated with anti-HoxA9 (Upstate Biotechnology, 
Charlottesville, VA); anti-c-Myb; anti-PARP,  anti-caspase 7, anti-cleaved caspase-7, 
anti-IGF-1R, anti-ERK, anti-phospho ERK, anti-phospho Akt (ser473), anti-BAD, 
anti-phospho BAD (ser112), and anti-Pim-1 antibodies (Cell Signaling Technology, 
Beverly, MA); anti-Pax5 (BD Transduction Laboratories, San Diego, CA); anti-actin 
(Sigma, St. Louis, MO); anti-phosphotyrosine antibody (clone 4G10) (Upstate 
Biotechnology, Charlottesville, VA); anti-HnRNP70 (kind gift from Dr. Phillip Pekala, 
East Carolina University) or anti-β-tubulin primary antibodies, suspended in 5% nonfat 
milk/TBST or 5% BSA/TBST at the appropriate dilution for 2 hr to overnight. 
Membranes were washed in TBST 3 × for 10 min each then the membranes were 
incubated with the appropriate secondary antibody (1 : 5,000 dilution) suspended in 5% 
nonfat milk/TBST or 5% BSA/TBST, conjugated to horseradish peroxidase, for 1 hr. 
Membranes were washed 3 × for 10 min in TBST and visualized SuperSignal® West Pico 
chemiluminescent substrate according to manufacturer’s instructions.  
2.3.1 Immunoprecipitation  
Cells were washed in phenol red free XVIVO-10 medium and then cultured in the 
presence or absence of A12 mAb (15 ug/ml) and 4HT (1 µM). Cells were treated with 
recombinant human IGF-1 (100 ng/ml) for 5 minutes followed by the addition of 1 mM 
EGTA, 10 mM NaF, 1 mM sodium pyrophosphate, and 0.1 mM β-glycerophosphate. 
Cells were washed in ice cold PBS and lysed in buffer containing 50 mM Tris-HCl (pH 
7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM phenylmethylsulfonyl 
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fluoride, 1 mM Na3VO4, 1 mM EGTA, 10 mM NaF, 1 mM sodium pyrophosphate, and 
0.1 mM β-glycerophosphate. 250 µg of cellular protein in 300 µl of lysis buffer was 
precleared for 2 hr at 4°C with 20 µl of protein A/G plus-agarose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA). Immunoprecipitation was performed overnight at 4°C 
with 2 µg of anti-IGF-1Rα antibody (clone 24-31) (Thermo Fischer Scientific, Fremont, 
CA). Twenty microliters of beads were added to samples and were incubated at 4°C for 2 
hr. Beads were collected by centrifugation at 1000 × g for 5 min, washed twice in ice 
cold lysis buffer, and western blotting was performed as described using an 
anti-phosphotyrosine antibody (clone 4G10) (Upstate Biotechnology, Charlottesville, 
VA), per manufacturer’s instructions, to detect phosphorylation of the 
co-immunoprecipitated IGF-1Rβ chain. IGF-1Rβ chain identity was confirmed by 
probing the blot with anti-IGF-1Rβ (Santa Cruz Biotechnology, Santa Cruz, CA). 
2.4 Electrophoretic Mobility Shift Assays 
Complementary oligonucleotides (upper strand shown) containing a consensus 
binding site for HoxA9 (ctgcgATGATTTACGACcgc) (148) were synthesized 
(Invitrogen, Carlsbad, CA). EMSA assays were performed using the DIG Gel Shift Kit, 
2nd Generation (Roche, Indianapolis, IN). Briefly, double-stranded, digoxegenin-labeled 
DNA and unlabeled probe were incubated with 10 µg of BLIN-2/HoxA9:ER or 
BLIN-2/MigR1 protein either in the presence or absence of 1 µg of anti-HoxA9 
polyclonal antibody (Upstate Biotech) in labeling buffer [1 µg of d(I-C), 1 µg d(A-T) plus 
2 µg BSA, in a final reaction volume of 20 µl]. Prior to the addition of DNA for EMSA, 
antibody and proteins were incubated together for 45 min at RT, prior to the addition of 
DNA. Labeled DNA targets were then incubated with each protein mixture for 30 min at 
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RT. Mixtures were run on a 6% non-denaturing polyacrylamide gel. Gel electrophoresis 
was performed in 0.25 × TBE (Tris-Borate-EDTA) buffer. Gels were transferred to 
PVDF membranes and signals were revealed using the DIG Nucleic Acid Detection Kit 
(Roche, Indianapolis, IN) per the manufacturer’s instruction. 
2.5 RT-PCR  
Total RNA was extracted from 5 × 104 cells using Tri-Reagent (Molecular 
Research Center, Cincinnati, OH, USA). Oligo-dT primed cDNA was synthesized as 
follows: 10 µl of RNA was incubated with 1.6 µl of 5 × RT buffer, 0.5 µl of DNAse I, 
and 0.5 µl of RNase inhibitor (Invitrogen, Carlsbad, CA) at 37°C for 1 hr, followed by 
heat inactivation at 75°C. To this reaction was added 2.4 µl of 5 × RT buffer, 2 µl 0.1 M 
DTT, 1 µl of Oligo-dT, 1 µl of 10 mM dNTPs, and 1 µl of Reverse Transcriptase 
(Invitrogen, Carlsbad, CA). Following 1 hr incubation at 42°C and 10 min heat 
inactivation at 75°C, 1 µl of this preparation was used for each PCR reaction.  
Each PCR reaction mixture contained 39 µl of H2O, 5 µl of 10 × Buffer 
(Invitrogen, Carlsbad, CA), 1.5 µl of 50 mM MgCl2, 1 µl of 10 mM dNTPs, 1 µl of each 
primer at 20 µM, 0.5 µl Taq polymerase (Invitrogen, Carlsbad, CA), and 1 µl of cDNA. 
For PCR reactions the primers and annealing temperatures were as follows: HoxA9 
forward 5’ - TGT GGT TCT CCT CCA GTT GAT AGA G - 3’, reverse 5’ - TCG GTG 
AGG TTG AAC AGT CGA G - 3’ at 50°C; IGF-1R forward 5’ - ACC ATT GAT TCT 
GTT ACT TC - 3’, reverse 5’ - ATA CTC TGT GAC ATT CTT AA - 3’ at 51°C; c-Myb 
forward 5’ - GTT TTC AGA ACA GTT CAA GT - 3’, reverse 5’ - TAC ACT TAG AGT 
AAT GCT TT - 3’at 55°C; mb-1 forward 5’ - GCT CCC CTA GAG GCA GCG ATT 
AAG GGC TCA - 3’,  reverse 5’ - AGG GTA ACC TCA CTC TTC TCC AGG CCA 
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GGC - 3’ 60°C; MLL/AF4 forward 5’ - CGT TCC TTG CTG AGA ATT TG - 3’, 
reverse 5’ - AAG CCC GTC GAG GAA AAG - 3’ at 55°C; and GAPDH forward 5’- 
TCC ATG CCA TCA GTG CCA CC - 3’, reverse 5’ - ATG AGC TTG ACA AAG TGG 
TC -3’ at 60°C.  
2.5.1 Southern Blot Analysis  
Ten microliters of each PCR product was separated on a 1.5 % agarose gel and 
transferred to a nylon membrane (Hybond-N, GE Healthcare, Piscataway, NJ). DNA was 
cross-linked to membranes by UV exposure followed by pre-hybridization with 25 ml of 
southern blot buffer (200 µM Tris-HCL, pH 7.5, 1 M NaCl), 0.1 % SDS (w/v) and 1 ml 
of boiled salmon sperm DNA (10 mg/ml) at 42°C for 3 hr in a hybridization oven.  
Following pre-hybridization the blots were hybridized at 42°C overnight with 
oligonucleotide probes internal to the PCR primers. Probes were labeled with digoxigenin 
(DIG) using the DIG Oligonucleotide 3’-End Labeling Kit, 2nd Generation (Roche, 
Indianapolis, IN) per the manufacturer’s instructions. The following probes were used: 
HoxA9, 5’ - TCA TGC GCG CTC CAC TCG GA - 3’; IGF-1R, 5’ - CTG CTC CTC 
TCC TAG GAT GA - 3’; c-Myb, 5’ - GAA TTG TAG CCA GTT GTT AAT - 3’; mb-1, 
5’ - GCT CCC CTA GAG GCA GCG ATT AAG GGC TCA - 3’; MLL/AF4, 5’ - TGC 
AGG GCT AGC CCG CCT CAG CCA CCT ACT - 3’; and GAPDH 5’ - TTC GTT GTC 
ATA CCA GGA - 3’. Following hybridization, membranes were washed at 42°C in 
pre-warmed 1 × SSC buffer (150 mM NaCl, 15 mM Na-Citrate, pH 7.0) and 0.1 % SDS 
3 × for 1 hr each. Hybridization signals were revealed using the DIG Nucleic Acid 
Detection Kit (Roche, Indianapolis, IN) per the manufacturer’s instruction. 
2.6 Transfection with siRNA  
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HoxA9 siRNA targeted to the sequence 5’-AAT CAA CAA AGA CCG AGC 
AAA-3’ was synthesized by Ambion (Austin, TX). Cells were transfected using an 
AMAXA Nucleofector per manufacturer’s instructions and analyzed 24 hr later by 
RT-PCR for HoxA9 and IGF-1R expression.  
2.7 ELISA Assays  
Phosphorylated IGF-1R was detected using the STAR phospo-IGF-1R 
(TYR1135/1136) ELISA kit from Millipore (Billerica, MA). The kit was used as per 
manufacture’s protocol, with 40 µg of whole cell lysates per well. Plates were read of 450 
nm using a Thermo Electron Corporation Multiskan EX plate reader.  
2.8 Propidium Iodide Cell Cycle Analysis 
 Cells were collected and resuspended in 1 ml of ice cold 1 × PBS and 2 ml of ice 
cold methanol. Cells were incubated on ice for 30 min then collected and resuspended in 
500 µl of 1× PBS and 0.2 µg/ml RNase A. The mixture was incubated at 37° for 30 min. 
200 µl of propidium iodide staining solution (0.25 mg/ ml propidium iodide, 0.25 mM 
EDTA, and 0.25% vol/vol Triton X-100) was added and incubated at room temperature 
for 30 min in the dark. Following incubation, flow cytometry was performed using a 
FACSCalibur flow cytometer and analyzed using CellQuest-Pro software and and 
ModFit LT™ 3.0,  as described previously (143).
  
CHAPTER 3: HoxA9 Induces IGF-1R Expression In B-Cell ALL 
3.1  Introduction 
The homeobox (HOX) gene family encodes a group of transcription factors that 
are preferentially expressed during embryonic development and hematopoiesis and are 
commonly deregulated in acute lymphoblastic leukemia (ALL) (88). In hematopoiesis, 
the role of these transcription factors is to tightly control and maintain stem cell 
differentiation and proliferation (77). HOX gene family members contain conserved 
sequences of 183 nucleotides encoding a 61 amino-acid, helix-turn-helix, DNA binding 
motif. The core homeodomain DNA binding motif recognizes the DNA sequence 
(T/G)NA(T/C) (148). In mammals there are 39 different class I HOX genes organized 
into four clusters (A, B, C, and D), located on four separate chromosomes. The clusters 
may be further grouped into subclasses based on their primary sequence into 13 paralog 
groups within each individual cluster. The mixed lineage leukemia (MLL) gene encodes a 
protein responsible for maintenance of HOX gene expression, and translocations of the 
MLL gene are present at a high frequency in acute leukemia (73). 
Deregulation of HoxA9 is associated with leukemia of both the myeloid and 
lymphoid lineages (74,149,150). Gene expression signatures of MLL-dependent T and B 
cell ALL show upregulated expression of HoxA9 (88). In normal hematopoiesis, HoxA9 
is strongly expressed in the CD34+ population of hematopoietic precursors and 
subsequently downregulated as cells differentiate into the various sub-populations of 
blood cell types (73). Overexpression of HoxA9 has been shown to perturb normal 
hematopoiesis in mice resulting in the development of leukemia (87). 
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Pim-1 (90,91), gp91Phox (93) and members of the Wnt gene family (94) have 
been reported to be targets of HoxA9 activity. However, a connection between HoxA9 
and growth receptor signaling has not been previously described. In the present study, we 
have made use of a novel system to evaluate whether HoxA9 expression alters stromal 
cell dependent growth. The pre-B cell line, BLIN-2, requires direct contact with viable 
bone marrow stromal cells for optimal survival and proliferation (142) and lacks 
expression of endogenous HoxA9. Parental BLIN-2 cells were stably transduced with an 
inducible HoxA9 retrovirus. Induction of HoxA9 increased the survival and proliferative 
capacity of BLIN-2 cells in the absence of stromal cell support, and resulted in surface 
expression of IGF-1R. The HoxA9-mediated proliferative effects in BLIN-2 were 
abrogated with specific inhibitors of IGF-1R. Furthermore, siRNA “knock-down” of 
endogenous HoxA9 expression in cells bearing the MLL/AF4 chromosomal translocation 
resulted in loss of IGF-1R expression. These results are the first to functionally 
demonstrate a link between HoxA9 overexpression, induction of IGF-1R expression and 
proliferation of leukemic cells. 
3.2 Results 
3.2.1  Expression of the HoxA9:ER fusion protein  
To determine how HoxA9 expression may contribute to the growth and survival 
of B-lineage acute leukemia, the stromal cell dependent pre-B ALL cell line, BLIN-2, 
was stably transduced with a 4-hydroxytamoxifen (4HT)-inducible HoxA9 retrovirus. 
This construct fuses the murine HoxA9 in frame with the hormone binding region of the 
human estrogen receptor and a 14 amino acid encoding V5 epitope tag (HoxA9:ER). GFP 
is expressed as a separately translated protein, under the control of an internal ribosomal  
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Figure 5: Retroviral transduction of BLIN-2 cells to generate stably transfected 
inducible BLIN-2/HoxA9:ER cells. A) Retroviral vector constructs. B) Post-sort FACS 
analysis of BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells.  
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entry site (IRES), in order to facilitate the identification of transduced cells (Fig. 5A). 
Cells were also transduced with the retroviral vector lacking the HoxA9 fusion gene 
(MigR1). Following retroviral transduction, BLIN-2/MigR1 and BLIN-2/HoxA9:ER 
cells were FACS purified to 97% and 92%, respectively (Fig. 5B).  
The HoxA9:ER fusion gene encodes a chimeric hormone-inducible protein, that is 
regulated by addition of the estrogen analog 4HT to the growth media (Fig. 6). In the 
absence of the hormone inducer, the fusion protein is largely retained in the cytoplasm 
and is rapidly targeted for degradation via the proteasome pathway (151). Similar 
inducible systems have been successfully used by others to study the activity of 
transcription factors and signaling molecules (152,153). The HoxA9:ER fusion protein is 
stabilized in the presence of 4HT, which permits HoxA9 to localize in the nucleus. To 
test regulation of HoxA9:ER activity in BLIN-2 cells, BLIN-2/MigR1 and 
BLIN-2/HoxA9:ER cells were grown in the presence or absence of 4HT and analyzed for 
HoxA9:ER protein expression in nuclear and cytoplasmic protein fractions. Little 
HoxA9:ER was observed in BLIN-2/HoxA9:ER cells cultured in the absence of 4HT. 
However, when cultured in the presence of 4HT, HoxA9:ER was readily detected in the 
nuclear protein fraction (Fig. 7). Pax5, a B-cell specific transcription factor, was included 
as a control for a nuclear specific protein (154). Actin was found almost entirely in the 
cytoplasm (155). This experiment confirms the stabilization and nuclear localization of 
the HoxA9:ER fusion protein in BLIN-2/HoxA9:ER cells treated with the estrogen 
analog 4HT.  
 
 
55 
Figure 6: Model for induction of the HoxA9:ER fusion protein. In the absence of 
estrogen, or the estrogen analog 4HT, the HoxA9:ER fusion protein is bound up by heat 
shock proteins (HSP) in the cytoplasm and rapidly targeted for proteolytic degradation. 
However, upon the addition of 4HT, the hormone analog out competes HSP for the 
binding domain of the ER because of a higher affinity for the binding site. This results in 
stabilization of the fusion protein which can subsequently translocates into the nucleus to 
activate the transcription of target genes.   
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Figure 7: 4HT-mediated induction of HoxA9 in stably transduced 
BLIN-2/HoxA9:ER cells. Whole cell lysate (W) was prepared from BLIN-2/MigR1 
cells (lanes 1 and 2), and cytoplasmic (C) and nuclear (N) proteins were prepared from 
BLIN-2/HoxA9:ER cells (lanes 3 – 6). 20 µg of protein per lane was separated on 8% 
SDS-PAGE gels followed by transfer to nitrocellulose membranes. Membranes were 
probed with the indicated antibodies. Cells were cultured in the presence or absence of 
1µM 4HT for 24 hr. 
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3.2.2  HoxA9:ER binds to a HoxA9 DNA consensus binding sequence 
EMSA analysis was performed to verify that HoxA9:ER was capable of binding 
to the HoxA9 DNA-binding consensus sequence. Protein lysates from BLIN-2/MigR1 
and BLIN-2/HoxA9:ER cells were incubated with a digoxegenin labeled probe 
(ctgcgATGATTTACGACcgc) and resolved through a non-denaturing polyacrylamide 
gel (Fig. 8). A shifted complex was observed when BLIN-2/HoxA9:ER lysate was 
incubated with the labeled probe (lane 6). This was competed away with excess unlabeled 
probe (lane 7). Pre-incubation of the lysate with anti-HoxA9 antibody resulted in a 
reduction in the intensity of the shifted band (lane 8), indicating that HoxA9 is part of this 
complex. No mobility shift was detected in lanes 2 – 5 using lysate from BLIN-2/MigR1, 
which lacks expression of endogenous HoxA9. These data indicate that the HoxA9:ER 
fusion protein is capable of binding the HoxA9 DNA binding sequence.  
3.2.3 BLIN-2/HoxA9:ER cells exhibit increased proliferation in the absence of 
stromal cell support 
To examine the effects of HoxA9:ER on proliferation and survival, 
BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells were cultured in the absence of stromal cell 
support with or without 1 µM 4HT for 5 days. Proliferation was determined by the 
MTT-assay, which measures mitochondrial respiration as a surrogate for cell number (Fig. 
9). BLIN-2/MigR1 cells showed little change in proliferation over the course of the 
experiment in the presence or absence of 4HT. However, BLIN-2/HoxA9:ER cells, both 
in the presence and absence of 4HT, showed increased proliferation up to day three. After 
day three, only BLIN-2/HoxA9:ER cells cultured with 4HT continued to proliferate. 
Proliferation of BLIN-2/HoxA9:ER cells in the absence of 4HT may be due to leaky acti- 
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Figure 8: HoxA9:ER binds a consensus HoxA9 DNA binding sequence in 
BLIN-2/HoxA9:ER cells. EMSA was used to assess DNA binding of HoxA9:ER. 10 µg 
of total protein from BLIN-2/MigR1 or BLIN-2/HoxA9:ER cells was incubated with 4 ng 
of a labeled consensus binding sequence for HoxA9 (lanes 2 - 9) in the presence or 
absence of 250X excess unlabeled probe (Competitor) (lanes 3, 5, 7, and 9) and l µg of 
anti-HoxA9 antibody (lanes 4, 5, 8, and 9). The top arrow marks the migration of the 
HoxA9:ER/DNA complex (lane 6). 
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Figure 9: HoxA9 activity promotes BLIN-2/HoxA9:ER proliferation in the absence 
of stromal cells. Proliferation of BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells was 
evaluated by a quantitative colorimetric assay used to detect cell survival and 
proliferation, the MTT assay. Cells were cultured for five days in media alone (squares) 
or media containing 1µM 4HT (triangles). At the indicated time points cells were assayed 
for relative proliferation (expressed as absorbance at 492nm). Results are compiled from 
five independent experiments. 
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vity of the HoxA9:ER fusion protein; however, 4HT is required for maintained 
proliferation. Thus, HoxA9:ER activity can promote stromal cell-independent 
proliferation of B-ALL cells.  
3.2.4 HoxA9 activity alters protein levels of c-Myb 
c-Myb has been reported to be a potential target of HoxA9 in leukemias 
expressing the MLL/ENL oncoprotein (92). c-Myb protein expression was evaluated in 
whole cell protein lysates prepared from parental BLIN-2 and BLIN-2/HoxA9:ER cells 
cultured with 4HT. c-Myb expression was increased in BLIN-2/HoxA9:ER cells as 
compared with parental BLIN-2 (Fig. 10A). To further verify increased c-Myb protein 
expression upon induction of HoxA9 activity, cytoplasmic and nuclear protein fractions 
were prepared from parental and BLIN-2/HoxA9:ER cells stimulated with 4HT and 
analyzed for c-Myb expression (Fig. 10B). c-Myb nuclear protein expression was 
increased in 4HT treated BLIN-2/HoxA9:ER cells compared with parental BLIN-2 cells, 
indicating that HoxA9 activity resulted in increased c-Myb protein levels.  
3.2.5 HoxA9 activation induces surface expression of IGF-1R  
As c-Myb has been reported to regulate IGF-1R expression (156-158), 
BLIN-2/HoxA9:ER cells were examined by RT-PCR for expression of IGF-1R. IGF-1R 
expression was detected in BLIN-2/HoxA9:ER cells treated with 4HT. No detectable 
IGF-1R expression was detected in untreated BLIN-2/HoxA9:ER cells or BLIN-2/MigR1 
empty vector control cells (Fig. 11A). The RS4;11 cell line bears the MLL/AF4 
translocation and has been reported to overexpress endogenous HoxA9 (159). IGF-1R 
gene expression was also observed in these cells.  
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Figure 10: c-Myb is increased in the presence of HoxA9 activity. A) Total cellular 
protein was prepared from parental BLIN-2 and BLIN-2/HoxA9:ER cells grown in the 
presence 1 µM 4HT for 24 hr. 20 µg of total cellular protein was resolved on 8% 
SDS-PAGE gels and transferred to PVDF membranes. Membranes were sequentially 
probed with antibodies against HoxA9, c-Myb and β-tubulin. B) Cytoplasmic (C) and 
nuclear (N) proteins were prepared from BLIN-2 and BLIN-2/HoxA9:ER cells cultured 
with 1  µM 4HT, followed by western blot analysis. Actin is found predominantly in the 
cytoplasm. Pax5 and p70 are nuclear proteins. 
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Figure 11: HoxA9 induces expression of IGF-1R A) RT-PCR amplification of IGF-1R 
in BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells cultured in the presence of 1 µM 4HT. 
RS4;11 is a t(4;11) cell line that expresses endogenous HoxA9. -RT = no reverse 
transcriptase. H2O = no cDNA template. B) Western analysis of parental BLIN-2 and 
BLIN-2/HoxA9:ER cells cultured with 1 µM 4HT for 24 hr. C) FACS analysis of 
BLIN-2 and BLIN-2/HoxA9:ER cells cultured with 1 µM 4HT for 24hr. 
BLIN-2/HoxA9:ER cells exhibited low, but detectable levels of IGF-1R. Surface IGF-1R 
expression was not observed in parental BLIN-2 cells. Dotted lines are isotype matched 
negative controls; solid lines are anti-IGF-1R stained cells. D) IGF-1R expression in 
RS4;11 and SEMK2. Whole cell lysates from BLIN-3, RS4;11 and SEMK2 were 
analyzed for IGF-1R protein expression via western blotting. IGF-1R expression was 
only observed in the RS4;11 and SEMK2 cells lines known to express HoxA9. BLIN-3, 
that does not express HoxA9, did not express IGF-1R. 
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      IGF-1R protein expression was detected by western blot analysis in 4HT treated 
BLIN-2/HoxA9:ER cells, while no IGF-1R protein was detected in parental control cells 
(Fig. 11B). Surface expression of IGF-1R was next examined by flow cytometry (Fig. 
11C). IGF-1R surface expression was detected on BLIN-2/HoxA9:ER cells but not on the 
parental BLIN-2 cells. 
Detection of IGF-1R expression in RS4;11 cells raised the possibility that IGF-1R 
expression may correlate with HoxA9 expression in cells bearing the MLL/AF4 
translocation. To test this hypothesis, three MLL/AF4 cell lines were examined by 
western analysis for IGF-1R expression. The SEMK2 and BLIN-3 cell lines both express 
the MLL/AF4 fusion protein. However, BLIN-3 cells lack expression of endogenous 
HoxA9 (143,144), have retained an absolute requirement for growth factor/stromal cell 
contact for optimal growth and proliferation, and are IL-7 dependent (143). In contrast, 
RS4;11 and SEMK2 cells do not require stromal cell contact or exogenous IL-7 for 
survival and proliferation. IGF-1R protein expression was observed in the growth 
factor-independent cell lines SEMK2 and RS4;11 (Fig. 11D). Interestingly, IGF-1R 
expression was not observed in the stromal cell dependent cell line, BLIN-3. Collectively, 
these results suggest that HoxA9 induces expression of IGF-1R, which in turn, promotes 
growth factor/stromal cell independent growth in leukemic cells. 
3.2.6 Inhibition of IGF-1R blocks proliferation of BLIN-2/HoxA9:ER 
IGF-1R has been reported to relieve leukemic cells of growth factor dependency 
(127,128). To determine whether IGF-1R signaling promotes enhanced proliferation of 
pre-B cell ALL, BLIN-2/HoxA9:ER and BLIN-2/MigR1 cells were cultured on stromal 
cells with 4HT in the presence or absence of the IGF-1R tyrosine kinase inhibitor 
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AG1024 (1 µg/ml) (Fig. 12A, and B). BLIN-2/HoxA9:ER cells cultured in the presence 
of 4HT showed about an 8-fold increase in proliferation after 10 days of culture (Fig. 
12A). BLIN-2/HoxA9:ER proliferation was decreased in the presence of AG1024. At day 
5 there was nearly a 1.5-fold decrease in the proliferation of BLIN-2/HoxA9:ER cells 
treated with AG1024, and by day 10 these cells showed a 2-fold reduction in proliferation, 
as compared to cells treated with 4HT alone. BLIN-2/MigR1 cells cultured with 4HT 
exhibited nearly 2-fold less proliferation than the BLIN-2/HoxA:ER cells (Fig. 12B). 
These cells exhibited little decreased proliferation when treated with AG1024.  
3.2.7 Monoclonal antibody inhibition of the IGF-1R receptor 
In a series of separate and independent experiments, BLIN-2/HoxA9:ER cells 
were treated with the anti-IGF-1R monoclonal antibody, A12. A12 is an IGF-1R specific 
monoclonal antibody that possesses high affinity for the IGF-1R receptor and blocks 
binding of IGF-1 (136). Binding of A12 to the IGF-1R receptor results in the rapid 
internalization and degradation of the receptor, thus inhibiting IGF-1R signaling and 
reducing cell surface receptor levels (136). A12 has been reported to inhibit growth of 
various cancer cell lines, including multiple myelomas, and has shown strong antitumor 
activity in nude mouse models (136,160). 4HT-treated BLIN-2 and BLIN-2/HoxA9:ER 
cells were cultured in the presence of 15 µg of A12 mAb (Fig. 12C, and D). A12 
significantly inhibited proliferation of BLIN-2/HoxA9:ER cells cultured with 4HT (Fig. 
12C). A12 treatment had no effect on proliferation of parental BLIN-2 cells (Fig. 12D). 
These results suggest that HoxA9-mediated expression of IGF-1R is responsible for the 
increased proliferative capacity of BLIN-2/HoxA9:ER cells.   
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Figure 12: Inhibition of IGF-1R reduces proliferation. A–B) Inhibition of IGF-1R 
signaling reduces BLIN-2/HoxA9:ER proliferation in the presence of stromal cell support. 
BLIN-2/HoxA9:ER cells (A) cultured with stromal cells for 10 days in the presence of 1 
µM 4HT (○) or in the presence of 1 µM 4HT plus 1 µg/ml of the IGF-1R inhibitor, 
AG1024 (). BLIN-2/HoxA9:ER cells (B) were cultured as described, in the presence of 
1 µM 4HT alone (■) or with 1 µM 4HT plus 1 µg/ml of AG1024 (▲). Proliferation was 
determined by colorimetric assay and is presented as absorbance at 492 nm. Data are 
from 5 independent experiments. * denotes statistical significance (p ≤ 0.0001). C–D) 
Treatment with anti IGF-1R monoclonal antibody inhibits proliferation of 
BLIN-2/HoxA9:ER cells. BLIN-2/HoxA9:ER cells (C) were cultured on stromal cells 
with 1  µM 4HT to induce activity of HoxA9:ER, in the presence (♦) or absence (▲) of 
the anti-IGF-1R antibody, A12 (15 µg). Parental BLIN-2 cells (D) cultured with 1 µM 
4HT with (▼) or without A12 mAb (■). Proliferation was determined via the MTT assay. 
* denotes statistical significance (p < 0.02). Data are from 5 independent experiments. 
E–F) Inhibition of IGF-1R signaling reduces proliferation of RS4;11 cells. RS4;11 cells 
were cultured in the presence or absence of 15 µg A12 monoclonal antibody (E: untreated, 
■; A12 only, ▼) and 50 ng of IGF-1 (F: IGF-1 only, ■; IGF-1 and A12, ▲). 
Proliferation was determined via the MTT assay. Data are from 3 independent 
experiments. * denotes statistical significance (p < 0.05).   
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3.2.8 Blocking IGF-1R signaling in RS4;11 cells inhibits proliferation  
To test whether blocking IGF-1R signaling would be effective at inhibiting the 
proliferation of an MLL-positive leukemia expressing endogenous HoxA9, RS4;11 cells 
were cultured in the presence or absence of A12 mAb. A12 treatment resulted in 
significant growth inhibition of RS4;11 cells (Fig. 12E). A12 growth inhibitory effects 
were observed as early as day 2. A12 treatment was not sufficient to completely inhibit 
the proliferation of RS4;11 cells thus there are likely other factors involved that 
contribute to the proliferation of these cells. To determine whether the observed RS4;11 
growth effects were specific for IGF-1R inhibition, RS4;11 cells were cultured in the 
presence of IGF-1 or IGF-1 plus A12 (Fig. 12F). Treatment with IGF-1 abrogated the 
effects of the A12 antibody resulting in increased proliferation of the A12 treated cells. 
These results indicate that inhibition of IGF-1R has an anti-proliferative effect on cells 
overexpressing HoxA9.  
3.2.9 Loss of endogenous HoxA9 expression reduces IGF-1R expression in 
MLL/AF4 positive leukemia  
To test whether loss of endogenous HoxA9 affects IGF-1R expression in pre-B 
cell ALL, RS4;11 cells were transfected with increasing concentrations of HoxA9 siRNA 
and RT-PCR was used to evaluate HoxA9 mRNA levels 24 hr post-transfection (Fig. 13). 
Abrogation of HoxA9 gene expression with siRNA resulted in a loss of IGF-1R and 
c-Myb expression. Expression of the B-lineage specific gene mb-1 (Igα) and the 
MLL/AF4 fusion gene was not affected by the siRNA. This result provides strong 
evidence that endogenous HoxA9 is required for maintenance or induction of IGF-1R 
expression. 
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Figure 13: Loss of endogenous HoxA9 expression abrogates IGF-1R expression. 
RS4;11 cells were mock transfected or transfected with the indicated amounts of HoxA9 
siRNA (µg), and RT-PCR was used to analyze mRNA levels from cells after 24 hr 
culture. Shown is the negative image of an ethidium bromide gel. –RT = no reverse 
transcriptase. Mock = mock transfected. H2O = no cDNA template. 
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3.3.1 Expression of IGF-1. 
RT-PCR was used to determine whether the transduced BLIN-2 cell lines, the 
parental cell line and the stromal cell monolayers express IGF-1. As shown in Fig. 14, the 
stromal cells express the IGF-1 gene. In addition, IGF-1 expression was observed in 
BLIN-2, BLIN-2/MigR1 and BLIN-2/HoxA9:ER. No alteration in IGF-1 expression was 
observed upon induction of HoxA9 activity with the addition of 4HT (lanes 5, and 6). 
IGF-1 expression was also observed in RS4;11 cells (data not shown). These results 
suggest that HoxA9 does not regulate the expression of IGF-1, although this growth 
factor is expressed by both the leukemic cells and the supporting stromal cells. 
3.3.2 Phosphorylation of IGF-1R.  
To determine if IGF-1R is phosphorylated in BLIN-2/HoxA9:ER cells, we 
performed immunoprecipitation of IGF-1R from cells subjected to the treatments shown 
if Figure 15. IGF-1Rβ was co-immunoprecipitated using an antibody against the 
IGF-1Rα chain. Phosphorylated IGF-1Rβ was detected with an anti-phosphotyrosine 
antibody. Western blot analysis for phosphotyrosine residues revealed phosphorylated 
IGF-1R was only detected in BLIN-2/HoxA9:ER cells in the presence of both 4HT and 
IGF-1 (Fig. 15A). Additional, treatment with the A12 mAb inhibited phosphorylation of 
the receptor in these cells. To verify these results, we performed an ELISA assay to 
detect IGF-1Rβ phosphorylation (Fig. 15B). There was a 4.5-fold increase in IGF-1R 
phosphorylation in BLIN-2/HoxA9:ER in the presence of both 4HT and IGF-1 as 
compared to parental controls. IGF-1R phosphorylation in BLIN-2/HoxA9:ER cells was 
inhibited by treatment with the A12 mAb. IGF-1R phosphorylation in BLIN-2/HoxA9:E- 
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Figure 14: IGF-1 Gene Expression. RT-PCR was performed to access IGF-1 gene 
expression in the indicated cells. Where indicated, cells were treated for 24 hours with 
4HT (+4HT) prior to analysis. Shown is a Southern blot of the PCR products separated 
on a 1.5% agarose gel. H2O = no cDNA template. 
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R cells was not detected in the absence of IGF-1 treatment and this is likely due to the 
sensitivity of detection for the assays used. 
3.4 Conclusions 
 Overexpression of HOX genes has been widely associated with a variety of 
leukemias, including those bearing aberrations of the MLL gene (63). While several 
studies have indicated that enforced HOX gene expression in murine models promotes 
leukemogenesis, the specific HOX-regulated mechanism(s) and pathways that 
promulgate leukemic cell growth and survival are not known. 
In this study, we have used a stromal cell dependent model of B-lineage ALL to 
determine how HoxA9 activity may promote stromal cell/growth factor independence. 
Using an inducible system, we found that HoxA9 activity resulted in prolonged 
proliferation in the absence of stromal cell support and that induction of HoxA9 activity 
resulted in IGF-1R expression. Inhibition of IGF-1R using either blocking antibodies 
(A12) or kinase inhibitors (AG1024) abrogated the proliferative effects in the presence of 
HoxA9 induction/activity. These findings were extended into cells that overexpress 
endogenous HoxA9 as a result of the MLL/AF4 oncoprotein. IGF-1R expression was 
found in SEMK2 and RS4;11 cells, both of which express MLL/AF4 and HoxA9. 
IGF-1R expression was not observed in BLIN-3 cells that express MLL/AF4, but lack 
endogenous HoxA gene expression (144). Proliferation of the factor independent cell line, 
RS4;11, was repressed upon inhibition of IGF-1R. siRNA “knock-down” of endogenous 
HoxA9 in RS4;11 cells resulted in loss of IGF-1R expression. 
Several lines of evidence suggest a role for IGF-1 and IGF-1R in leukemia. High 
levels of serum IGF-1 correlate with childhood leukemia and high birth weight (124). Si- 
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Figure 15: A12 inhibits IGF-1R phosphorylation in BLIN-2/HoxA9:ER cells. A) 
BLIN-2, BLIN-2/MigR1, and BLIN-2/HoxA9:ER cells were cultured in the presence of 
4HT (4HT), IGF-1 (IGF-1), 4HT and IGF-1 (4HT + IGF-1), or 4HT, IGF-1  and A12 
(A12). Total protein was isolated and immunoprecipitation (IP) of the IGF-1Rα subunit 
of IGF-1R was performed followed by western blot analysis of phosphorylated tyrosine 
(P-Tyr) residues on the IGF-1Rβ chain. B) Phosphorylated IGF-1R was detected by 
ELISA. Cells were cultured as described above and ELISA was performed using 40 µg of 
total cellular protein. Plates were read at 450 nm and results are presented as fold increase 
in IGF-1R phosphorylation relative to untreated controls. 
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gnaling via IGF-1/IGF-1R interactions have been shown to participate in the growth of 
survival of multiple myeloma cells (139,160). IGF-1R expression has been reported in 
AML blasts, and IGF-1 is capable of stimulating AML cell proliferation (126-128,161). 
Several studies have indicated that inhibition of IGF-1R signaling results in a reduction 
of cell proliferation and induction of apoptosis, particularly in AML (126-128). 
Our data indicate that one mechanism of HOX-mediated cell proliferation is 
through expression and subsequent activation of the IGF-1R receptor. IGF-1R has been 
reported to relieve leukemic cells of cytokine dependency (127,128). IGF-1R activity is 
also implicated in promoting the growth of several solid tumors, such as breast, prostate 
and colon, in which aberrant HOX-gene expression has also been reported (114,115). 
IGF-1R has been reported to be regulated by the c-Myb transcription factor (156-158). In 
a recent report, expression of MLL/ENL resulted in increased c-Myb expression (92). In 
our study, c-Myb levels were increased upon induction of HoxA9 activity. 
Our data suggest a model in which overexpression of HoxA9 results in increased 
expression of c-Myb and induction of IGF-1R expression. This effect would, in-turn, 
promote stromal cell/growth factor independent growth and survival, provided that IGF-1 
was present. Our data indicate that IGF-1 is expressed by both the stromal cells and 
leukemic cells used in this system (Fig. 14), indicating autocrine and paracrine receptor 
activation. 
Work from the laboratory of Martelli et al. (126) indicates that autocrine signaling 
from IGF-1 and IGF-1R promotes the growth of AML cells. These investigators reported 
that inhibition of IGF-1R in AML cells induced dephosphorylation of IGF-1R and 
apoptosis. In this study chemoresistance in AML cells correlated with IGF-1 secretion. 
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As HoxA9 is frequently overexpressed in AML (74), our results, documenting HoxA9 
mediated induction of IGF-1R expression, is consistent with this study. 
Therapeutics targeting IGF-1R have been successful in a variety of oncogenic 
settings (139,162). IGF-1R activation affects multiple cellular pathways leading to 
increased proliferation, loss of apoptotic sensitivity and anchorage-dependent growth (96). 
In addition, IGF-1R signaling is required for normal B-cell development, during the 
pro-B to pre-B cell transition (163,164). One study demonstrated that proliferation of the 
pre-B ALL cell line, REH, is inhibited in a dose-dependent manner by monoclonal 
antibodies against IGF-I and IGF-1R (129). Furthermore, treatment of 
IGF-1/insulin-dependent hematopoietic precursor cell lines with anti-IGF-1R monoclonal 
antibodies induced growth arrest (136,160). Our findings suggest that inhibition of 
IGF-1R may be an effective approach for treatment of leukemia or other cancers that 
exhibit elevated HOX-gene expression, either as a stand-alone therapy or in combination 
with other approaches. Eighty percent of infant ALL is associated with MLL-aberrations, 
for which overexpression of HoxA9 is a hallmark (149). In addition, high levels of serum 
IGF-1 and high birth weight have been reported to correlate with infant ALL, the 
so-called big baby hypothesis (124). Thus, one area in which inhibition of IGF-1R may 
be of benefit is as a potential therapeutic in MLL positive infant ALL. 
In summary, our present data support a novel mechanistic role for HoxA9 activity 
in the promotion of leukemic cell growth; via induction of IGF-1R expression. This 
pathway will yield new potential targets for the treatment of leukemia and other cancers 
that involve HOX gene overexpression. 
 
  
CHAPTER 4: HoxA9 Protects B-Lineage All Cells From Apoptosis Induced 
By Stromal Cell Withdrawal 
4.1 Introduction 
HOX genes, first described in Drosophila melanogaster, encode a family of 
transcription factors involved in cell fate determination during embryogenesis. These 
genes also play a critical role in hematopoietic stem cell differentiation and proliferation. 
However, the exact molecular pathways regulated by HOX gene expression in 
hematopoietic cell growth and differentiation have not been fully elucidated, but a variety 
of studies indicate that altered HOX expression can influence differentiation and growth 
factor responses (73). HoxA9 is the most highly expressed HOX gene in the 
hematopoietic stem cell compartment, and plays a fundamental role in hematopoietic 
stem cell self renewal (94). Several animal studies using knockout mice have 
demonstrated that aberrant HoxA9 expression can perturb normal hematopoiesis resulting 
in developmental defects in both myeloid and lymphoid lineages (84,85,165). Depending 
upon the availability of co-factors, such as Meis1, HoxA9 has been shown to be 
transforming in mice (87). Not surprisingly, the deregulation of HoxA9 gene expression, 
as the result of genetic mutation, is the factor most highly associated with human acute 
leukemia. Overexpression of HoxA9 is commonly found in a variety of acute leukemias 
and has been reported to result in proliferative expansion of hematopoietic 
stem/progenitor cells at the expense of mature compartments (86). HoxA9 may also act to 
promote tumor cell proliferation and survival in situations where other abnormalities are 
likely the initial transforming event, such as MLL-translocations (166-168). 
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The data presented in Chapter 3 indicate that HoxA9 activity in BLIN-2 cells 
induces surface expression, and signaling through, the insulin-like growth factor-1 
receptor (IGF-1R) resulting in increased cellular proliferation (169). Signaling through 
IGF-1R activates two major intracellular signaling pathways, the PI3K/Akt pathway and 
the MAPK/ERK kinase pathway (170). Signaling through the MAPK/ERK pathway is 
principally associated with regulation of cellular proliferation (95,171). For numerous 
cell types, signaling through the PI3K/Akt pathway is associated with survival and 
protection from apoptosis (95,172). Hence, we next sought to evaluate the apoptotic 
sensitivity of BLIN-2 cells in the context of HoxA9 activity and IGF-1R signaling. We 
report here that induction of HoxA9 activity in BLIN-2 cells results in protection from 
apoptosis induced by growth factor/stromal cell withdrawal. This effect was independent 
of IGF-1R signaling. Induction of HoxA9 activity increased expression of the Pim-1 
proto-oncogene and increased BAD phosphorylation in the absence of growth 
factor/stromal cell support. Thus, providing an mechanism for apoptotic resistance 
independent of IGF-1R. Collectively, these data support a model in which HoxA9 
promotes leukemic cell proliferation, through induction of IGF-1R expression and 
signaling, and resistance to apoptosis through a pathway independent of IGF-1R 
signaling. 
4.2  Results 
4.2.1  HoxA9 protects BLIN-2 cells for apoptosis 
To determine whether BLIN-2 cells, stably transduced with an inducible HoxA9 
retrovirus (BLIN-2/HoxA9:ER) (169), are protected from apoptosis induced by stromal 
cell/growth factor withdrawal, BLIN-2 and BLIN-2/HoxA9:ER cells were cultured in the  
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Figure 16: HoxA9 protects BLIN-2 from stromal withdrawal induced apoptosis. 
Total cellular protein from BLIN-2 and BLIN-2/HoxA9:ER (HoxA9) cells cultured in the 
presence (+Stromal Cells) or absence of stromal cell support (-Stromal Cells), and in the 
presence or absence of β-estradiol (β-EST) to induce HoxA9 activity was prepared. Total 
cellular protein (20 µg) was resolved on 12% SDS-PAGE gels and transferred to PVDF 
membranes. Membranes were sequentially probed with antibodies against PARP, cleaved 
caspase-7, total caspase-7 and β-tubulin. β-tubulin is a loading control. Total = uncleaved 
PARP, cleaved = cleaved PARP, and p20 = cleaved caspase-7 product. 
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presence or absence of stromal cell support for 4 days. Additionally, cells were cultured 
in the presence or absence of β-estradiol to induce HoxA9 activity (Fig. 16). Western blot 
analysis was performed to evaluate the cleavage status of caspase-7 and the caspase-7 
substrate, poly (ADP-ribose) polymerase (PARP). These markers indicate induction of 
apoptosis due to loss of pro-survival signals. BLIN-2 and BLIN-2/HoxA9:ER cells 
cultured in the presence of stromal cell support showed no detectable cleavage products 
of either caspase-7 or PARP. In the absence of stromal cell support, and β-estradiol, both 
BLIN-2 and BLIN-2/HoxA9:ER cells showed detectable caspase-7 and PARP cleavage 
products. However, upon treatment with β-estradiol to induce HoxA9 activity, caspase-7 
and PARP cleavage products were reduced in BLIN-2/HoxA9:ER cells. β-estradiol 
produced a slight antiapoptotic effect in BLIN-2 cells in the absence of stromal cell 
support.   
BLIN-2 and BLIN-2/HoxA9:ER cells were cultured as described above and 
stained with propidium iodide prior to flow cytometric analysis (Fig. 17A, and B). 
Consistent with the cleavage of caspase-7 and PARP, BLIN-2 cells showed a significant 
increase in sub-G1 events that represent the apoptotic population of cells. 
BLIN-2/HoxA9:ER cells had a slightly increased sub-G1 which was not statistically 
significant. Together these results suggest that HoxA9 protects BLIN-2 cells from 
apoptosis induced by stromal cell/growth factor withdrawal. 
4.2.2 HoxA9-mediated protection from apoptosis is independent of IGF-1R  
 To determine whether signaling through the IGF-1R receptor is responsible for 
the resistance to apoptosis observed in BLIN-2/HoxA9:ER cells, BLIN-2 and the BLIN-2 
derived cell lines were cultured in the presence or absence of stromal cell support. In the  
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Figure 17: Propidium iodide cell cycle analysis.  A) A representative experiment of 
BLIN-2 and BLIN-2/HoxA9:ER cells cultured in the presence or absence of stromal cell 
support and analyzed for cell cycle analysis using propidium iodide DNA staining. B) 
Combined results from three separated experiments of propidium iodide cell cycle 
analysis of BLIN-2 and BLIN-2/HoxA9:ER cells cultured in the presence or absence of 
stromal cell support. Data is expressed as percent apoptotic cells. * denotes statistical 
significance (p= 0.0388). 
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absence of stromal cell support, cells were additionally cultured in the presence or 
absence of the anti-IGF-1R monoclonal antibody, A12 (Fig. 18A, and B). Treatment with 
A12 results in inhibition of IGF-1R signaling, as well as internalization and degradation 
of the IGF-1R receptor (136). First, to determine whether A12 treatment was reducing 
IGF-1R expression on BLIN-2/HoxA9:ER cells, immunoprecipitation was performed 
followed by western blot analysis for IGF-1R expression (Fig. 18A). IGF-1R expression 
was detected only in BLIN-2/HoxA9:ER cells (lanes 3 and 6) and treatment with A12 
resulted in a loss of detectable IGF-1R expression in BLIN-2/HoxA9:ER (lane 9). Next, 
western blot analysis was performed on the cells described above to evaluate PARP 
cleavage (Fig. 18B). Minimal PARP cleavage was detectable in all cells cultured in the 
presence of stromal cell support. In the absence of stromal cell support, BLIN-2 and 
BLIN-2/MigR1 cells showed high levels of cleaved PARP (lanes 4, 5, 7, and 8). 
BLIN-2/HoxA9:ER cells cultured in the absence of stromal cell support demonstrated 
little PARP cleavage (lane 6). Interestingly, this observation was not affected by addition 
of A12 (lane 9). These results suggest that protection from PARP cleavage in 
BLIN-2/HoxA9:ER cells was independent of IGF-1R signaling. Furthermore, 
BLIN-2/HoxA9:ER cells exhibited increased levels of phosphorylated ERK in the 
presence or absence of stromal cell support, but no change in Akt phosphorylation was 
observed (data not shown). These results are consistent with a model in which the 
HoxA9-mediated induction of IGF-1R expression, and subsequent activation of the 
receptor, promote proliferation of BLIN-2/HoxA9:ER cells (169) through activation of 
the MAPK/ERK signaling pathway, but not apoptotic resistance through the PI3K/Akt 
signaling pathway.  
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Figure 18: Protection from PARP cleavage is independent of IGF-1R expression. 
Total cellular protein was prepared from BLIN-2, BLIN-2/MigR1 (MigR1) and 
BLIN-2/HoxA9:ER (HoxA9) cells cultured in the presence (+Stromal Cells) or absence 
of stromal cell support (-Stromal Cells), and in the presence or absence of the A12 
monoclonal antibody. Immunoprecipitation was performed for IGF-1R (IP) followed by 
western blot analysis (WB) for receptor expression, as described. Cells were also 
analyzed for PARP cleavage via western blotting. β-tubulin serves as a loading control. 
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4.2.3 Pim-1 is a HoxA9 target in BLIN-2 cells 
 The Pim-1 proto-oncogene is reported to be a direct transcriptional target of 
HoxA9 in hematopoietic cells (90,91). The Pim-1 proto-oncogene is a serine/threonine 
kinase expressed in the hematopoietic and lymphoid tissues (173). Pim-1 plays a positive 
role in cell cycle progression at both the G1/S and G2/M transitions (173). To determine 
if BLIN-2/HoxA9:ER cells exhibit increased expression of Pim-1, western analysis was 
performed on BLIN-2, BLIN-2/MigR1, and BLIN-2/HoxA9:ER cells (Fig. 19A). Pim-1 
expression was greatly increased in BLIN-2/HoxA9:ER cells compared to the parental 
cell lines.  
4.2.4 BAD phosphorylation  
One of the targets of Pim-1 is the pro-apoptotic protein BAD which is 
phosphorylated on Ser112. Thus, a functional role of Pim-1 is preventing apoptosis 
through the inactivation of BAD (174). BAD is also phosphorylated at Ser136 and 
phosphorylation at both of these sites promotes binding of BAD to 14-3-3 proteins to 
prevent association with Bcl-2 and Bcl-xl and induction of apoptosis. To determine 
whether BAD phosphorylation is increased in BLIN-2/HoxA9:ER cells, BLIN-2, 
BLIN-2/MigR1 and BLIN-2/HoxA9:ER cells were cultured in the absence of stromal cell 
support and in the presence of β-estradiol to induce HoxA9 activity. Immunoprecipitation 
was performed for total BAD protein followed by western analysis for the BAD 
phospho-(ser) 14-3-3 binding motif (Fig. 19B). Phosphorylation of BAD was 
undetectable in parental cell lines; however, phosphorylated BAD was readily detectable 
in BLIN-2/HoxA9:ER cells. These results suggest that HoxA9 protects BLIN-2 cells 
from apoptosis through Pim-1–mediated phosphorylation of BAD. 
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Figure 19: Pim-1 expression and BAD phosphorylation are increased in the 
presence of HoxA9 activity. A) Total cellular protein (20 µg) was resolved on 8% 
SDS-PAGE gels and transferred to PVDF membranes. Membranes were sequentially 
probed with antibodies against Pim1, HoxA9, and β-tubulin. B) Total cellular protein was 
isolated from BLIN-2 and BLIN-2/HoxA9:ER cells cultured in the presence and absence 
of stromal cell support. Immunoprecipitation (IP) of total BAD was performed followed 
by western blot analysis (WB) of phosphorylated serine 14-3-3 binding motif or total 
BAD.   
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4.3 Conclusions 
 Overexpression of HoxA9 is highly associated with acute leukemia. However, 
molecular pathways activated by HoxA9 that promote survival and proliferation of 
leukemic cells have not been well defined. In Chapter 3 we reported that induction of 
HoxA9 activity in BLIN-2 cells induces surface expression and signaling through 
IGF-1R, resulting in an IGF-1R–dependent increase in cellular proliferation (169). 
IGF-1R has a wide distribution of expression and is essential for development and growth 
of normal tissues. Many studies have also implicated IGF-1R and its ligands, IGF-1 and 
IGF-2, in the development, maintenance, and progression of cancer (95). In tumor cells, 
overexpression of IGF-1R often leads to increased intracellular signaling through the 
PI3K/Akt and MAPK/ERK kinase pathways (170). Signaling through the PI3K/Akt 
pathway is associated with protection from apoptosis (95,172), and signaling through the 
MAPK/ERK pathway is associated with increased proliferation (95,171). Some studies 
also suggest that signaling through the PI3K/Akt pathway enhances and/or synergizes 
with MAPK/ERK signaling, providing a more robust pro-survival signal (100). Thus, 
signaling through IGF-1R can promote both cellular proliferation and apoptotic resistance 
through two different cellular signaling pathways. 
 Our previous findings addressed changes in the proliferative capacity of BLIN-2 
cells in the absence of stromal cell/growth factor support; however, we did not address 
the apoptotic sensitivity of BLIN-2 cells under these conditions. Therefore, we sought to 
evaluate the apoptotic status of BLIN-2 cells in the presence of enforced HoxA9 activity, 
but in the absence of stromal cell/growth factor support.  
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In the absence of growth factor/stromal cell support, BLIN-2/HoxA9:ER cells 
exhibited less cleaved PARP and caspase-7 compared to parental cells, indicating that 
HoxA9 is protective against apoptosis. These results were further confirmed by cell cycle 
analysis. Interestingly, cells treated with a specific inhibitor of IGF-1R exhibited no 
changes in PARP cleavage, indicating that the HoxA9-mediated protection from 
apoptosis is independent of IGF-1R signaling. Furthermore, while phosphorylation of Akt 
remained unchanged, BLIN-2/HoxA9:ER cells exhibited increased phosphorylation of 
ERK. This is consistent with a model in which signaling through IGF-1R promotes 
proliferation of BLIN-2 cells through activation of the MAPK/ERK pathway, while 
protection from apoptosis is independent of IGF-1R signaling through PI3K/Akt. 
The Pim-1 serine kinase has anti-apoptotic activity through phosphorylation of the 
pro-apoptotic protein BAD (174). BAD influences the integrity of the mitochondrial 
membrane, and release of cytochrome C, by associating with Bcl-2 and Bcl-xl and 
inhibiting their anti-apoptotic function (105). However, when phosphorylated, BAD is 
incapable of associating with Bcl-2 or Bcl-xl. Expression of Pim-1 is induced by a 
number of cytokines that signal through specific receptor tyrosine kinases, including 
PI3K/Akt (106,173). More recently, it was established that Pim-1 is a direct downstream 
target of HoxA9 in hematopoietic cells (91). Hu et al. showed that overexpression of 
HoxA9 in hematopoietic cells induces Pim-1–mediated phosphorylation of BAD, and 
partially rescued HoxA9–/– primitive mouse marrow cells from apoptosis (91). We 
examined BLIN-2/HoxA9:ER cells for Pim-1 expression and found that it was increased 
in the presence of HoxA9. As expected, BLIN-2/HoxA9:ER cells also exhibited 
increased phosphorylation of BAD upon growth factor/stromal cell withdrawal as 
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compared to the parental cell lines. These data provide an alternative pathway for the 
HoxA9-mediated resistance to apoptosis. Specifically, induction of HoxA9 in BLIN-2 
resulting in increased Pim-1 expression followed by increased phosphorylation of BAD. 
In Chapter 3 we reported that expression of the c-Myb proto-oncogene was 
increased upon induction of HoxA9 activity in BLIN-2 cells (169). Interestingly, Pim-1 
has been shown to function downstream of Ras to stimulate c-Myb transcriptional 
activity in a p100 dependent manner (175), and c-Myb is a known regulator of IGF-1R 
expression (156-158). Therefore, Pim-1 may serve a dual role in promoting both survival 
and proliferation of leukemic cells through 1) BAD phosphorylation and 2) increased 
IGF-1R expression via enhanced transcriptional activation of c-Myb. 
Pim-1 is involved in a number of cellular processes that control hematopoiesis 
and is frequently overexpressed or mutated in cancers (173). As such, Pim-1 serves as a 
promising target for chemotherapeutic intervention. Currently, highly selective and 
potent inhibitors of Pim-1 are in preclinical development (176), and at least one inhibitor 
is expected to begin phase I clinical trials later this year (205). Our data indicate that one 
mechanism of HoxA9-mediated cell proliferation is through expression and subsequent 
activation of the IGF-1R receptor. However, in our system IGF-1R signaling was not 
required for the survival of BLIN-2 cells in the absence of growth factor/stromal cell 
support. Therefore, targeting of IGF-1R alone in leukemic cells overexpressing HoxA9 
may not be sufficient in causing cell death, but may inhibit leukemic cell proliferation. 
Pim-1 inhibitors alone or combinatorial therapy using IGF-1R inhibitors along with 
Pim-1 inhibitors may prove to be more efficacious in the treatment of leukemia 
characterized by the overexpression of HoxA9. 
  
CHAPTER 5: DISCUSSION 
5.1  Summary  
Tumorigenesis is considered a stepwise process analogous to Darwinian evolution, 
in which the progressive acquisition of genetic mutations confers a selective growth 
advantage, causing cells to evolve from a state of normality to invasive cancers (177-179). 
Two key hallmarks of malignant transformation are uncontrolled proliferation and 
resistance to apoptosis (178). The means by which cancer cells obtain these traits is 
through defects in the regulatory networks that regulate normal cell proliferation and the 
apoptotic machinery. Understanding the mechanisms that govern these defects may lead 
to development of novel and more effective therapies. 
Leukemias represent a broad class of tumors characterized by the outgrowth of 
immature white blood cells in the BM and lymphoid tissues of the body. As with other 
types of cancer cells, leukemic cells are characterized by uncontrolled proliferation and 
resistance to programmed cell death. Acute leukemias account for the majority of 
leukemia-related deaths, and approximately 30 to 40% of acute leukemias are 
characterized by deregulation of HOX gene expression (88). HoxA9 is one of the most 
frequently overexpressed HOX genes in acute leukemia, and several studies have 
indicated that aberrant HoxA9 expression can perturb normal hematopoiesis resulting in 
developmental defects in both myeloid and lymphoid lineages (73). Whether the initial 
transforming event, or acting as a cofactor, little is known regarding the identity of 
pathways activated by HoxA9 overexpression that directly contribute to proliferation and 
survival of tumor cells. Therefore, the studies of this research project were designed to 
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test the hypothesis that HoxA9 overexpression promotes the growth and survival of acute 
leukemic cells through the activation of specific downstream signaling pathways. 
5.2 Model 
Altogether these data support a model in which HoxA9 promotes the proliferation 
and survival of pre-B ALL cells through an IGF-1R–dependent and –independent 
pathway. Presented in Figure 20 is the proposed model for the HoxA9-mediated effects in 
acute leukemic cells. Overexpression of HoxA9 results in an increase in c-Myb 
expression, and induction of IGF-1R. Increased IGF-1R on the cell surface sensitizes 
cells to ERK phosphorylation and IGF-1R–dependent proliferation. c-Myb is a known 
direct regulator of IGF-1R expression (156-158), and is a downstream target of HoxA9 in 
MLL/ENL transformed hematopoietic cells (92). Overexpression of HoxA9 also results 
in a reduction in apoptosis due to growth factor/stromal cell withdrawal. This effect is 
likely the result of increased Pim-1 expression and subsequent BAD phosphorylation by 
the kinase. Interestingly, Pim-1 has been shown to cooperate with p100 to enhance the 
transcriptional activity of the c-Myb protein (175). Therefore, HoxA9 induction of 
IGF-1R expression may be enhanced through increased Pim-1 regulation of c-Myb. 
c-Myb is the cellular homolog of v-myb, the transforming oncogene of the avian 
myeloblastosis virus, and encodes a transcription factor that plays a crucial role in the 
proliferation and differentiation of hematopoietic cells (180). Similar to the HoxA9, 
c-Myb is highly expressed in the immature compartment of hematopoietic cells and later 
downregulated as the cells mature through lineage specific developmental programs 
(180). c-Myb overexpression transforms cells in culture and results in acute leukemia in 
animals.(181) The c-Myb protein transactivates promoters with a spe
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Figure 20: Model for HoxA9-mediated Proliferation and Protection from Apoptosis. 
Induction of HoxA9 activity results in IGF-1R dependent increase in proliferation and 
increased c-Myb expression. HoxA9 induction also increases Pim-1 expression and 
protects cells from growth factor/stromal cell withdrawal induced apoptosis through a 
pathway independent of IGF-1R signaling.  
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us sequence, YAACBGYCR, where YAAC is absolutely required for DNA binding 
(182). Our results do not distinguish whether HoxA9 is directly regulating IGF-1R 
expression, or whether IGF-1R expression is induced indirectly through upregulation of 
c-Myb expression. The IGF-1R gene has a TATA-less promoter and most of the 
promoter activity is located in the proximal 416 bp upstream of the transcriptional start 
site (183,184). Further dissection of the 5'-flanking region outside of the core 416 bp has 
revealed cell type-specific patterns of promoter activity upstream of this core region 
(184). Sequence analysis of the IGF-1R 5'-flanking region revealed multiple putative 
HoxA9 consensus binding sequences, along with several c-Myb putative consensus 
binding sequences (Fig. 21). Thus, HoxA9 may directly regulate IGF-1R gene expression, 
through binding to the 5'-flanking region of the IGF-1R promoter, or indirectly through 
c-Myb upregulation. Furthermore, several of these consensus binding sequences have 
considerable overlap which might be important for synergistic activation of IGF-1R 
expression by HoxA9 and c-Myb. Interactions between HoxA9 and c-Myb have not been 
described. It would be interesting to investigate whether HoxA9 is capable of binding to, 
and transactivating the IGF-1R promoter alone. It would also be interesting to examine 
whether there is any physical interaction between HoxA9 and c-Myb, and whether these 
proteins can function together to increase IGF-1R expression. 
5.3 Significance 
These studies are the first to demonstrate a link between HoxA9 overexpression 
and growth factor receptor expression and signaling in acute leukemia. HoxA9 induction 
of IGF-1R expression and signaling represents one mechanism by which HoxA9 can 
promote leukemic cell survival and proliferation. Loss of responsiveness to microenviro- 
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Figure 21: 5'-Flanking sequence of the IGF-1R gene. Consensus DNA binding sequences for 
HoxA9 (blue boxes) and c-Myb (red letters, red underline). Doubled underlined c-Myb consensus 
sequence is absolutely required for c-Myb binding. Y = C or T; B = C or G or T; R = A or G; N = 
A or T or G or C. 
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GCGCTGTTGT TGTTTTCAAT GAACCTCTCC CAGCCCCGCA CTCCCCGCCC .......... 
GCCCGGGCTC CGCTCCGCAC GTCTTGGGGA ACCGGGCTCC GGTTTTTTGC .......... 
GCGGCGGCGC GGCGAGGCTG GGGCTCTTGT TTACCAGCAT TAACTCCGCT GAGCGGAAAA
AAAAAGGGAA AAAACCCGAG GAGGAGCGAG CGCACCAGGC GAACTCGAGA .......... 
CTCGCCTGTG ACCCGGACTT CGGGGCGATC TTGCGAACTG CGTCGCGCCC .......... 
-1460
-1160
-980
-920
-440
c-Myb Consensus Sequence = YAACBGYCR
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mental cues, such as growth factor or stromal cell-derived signals, is a critical step in 
leukemic progression (185,186). As leukemic cells lose the need for growth 
factor/stromal cell support for survival, there is no longer any selective pressure to retain 
those cells in discreet compartments of the BM. Thus, these cells can survive and 
continue to grow through the metastatic process.  
One way cancer cells become self-sufficient is through upregulation of growth 
factors and growth factor receptors. IGF-1R signaling is associated with protection from 
apoptosis, enhanced cellular proliferation, drug resistance, and anchorage independent 
growth (98). IGF-1 is produced primarily by the liver and stromal cells of the BM 
microenvironment (95), and IGF-1 appears to have endocrine, paracrine, or autocrine 
effects on the immune system (187) In normal B-cell development little is known 
regarding the stage at which IGF-1 acts (188). In vitro studies have demostrated that 
IGF-1 promotes the differentiation of pro-B cells into pre-B cells (163). However, studies 
utilizing IGF-1 knockout mice revealed that there are no defects in B-cell development in 
these animals (189). Other studies suggest that IGF-1 may act on mature B-cells to 
promote immunoglobulin production (190,191), although IGF-1R is expressed at low 
levels on mature B-cells (164). In leukemia, overexpression of IGF-1R has been shown to 
relieve cells of cytokine dependency (127,128). Autocrine signaling through IGF-1R has 
also been reported to promote the growth of AML cells and inhibition of IGF-1R 
signaling induces apoptosis in these cells (126). Martelli et al. also reported that 
chemoresistance of AML cells correlated with IGF-1 secretion (126). Furthermore, 
daunorubicin resistant leukemic cells, K562VCR, demonstrated an 11-fold increase in 
IGF-1R expression compared to parental K562WT cells (192). Interestingly, K562VCR 
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cells also showed an 8-fold increase in HoxB4 gene expression (192). Therefore, 
overexpression or activation of IGF-1R signaling may not only be a major determinant of 
the tumorigenicity of leukemic cells, but also of drug resistance.  
Activation of IGF-IR results in PI3K phosphorylation and subsequent 
downstream phosphorylation of Akt. Akt, in turn, can inhibit pro-apoptotic proteins, such 
as BAD, and inhibit initiation of apoptosis. IGF-1R receptor activation is also associated 
with induction of the MAPK/ERK signaling pathway, which is responsible for the 
mitogenic effects of IGF-1R signaling (98).  
Induction of HoxA9 activity in BLIN-2 cells prolonged survival and proliferation 
in the absence of growth factor/stromal cell support. However, this factor alone was not 
sufficient to completely alleviate the requirement for stromal cell contact for long-term 
survival and proliferation. A role for IGF-1R receptor numbers has been described in 
which a minimum number of receptors, 15,000 to 22,000, were required to render mouse 
embryonic fibroblasts competent to grow in serum-free medium supplemented solely 
with IGF-I, and for growth in soft agar, 30,000 receptors per cell was the minimum 
requirement (193).Therefore, one possible explanation may be an insufficient number of 
receptors on the cell surface. Another possible explanation may be a defect in the 
PI3K/Akt signaling pathway, as no changes in Akt phosphorylation were observed upon 
induction of IGF-1R signaling, the primary signaling pathway activated by IGF-1R (95). 
This observation may also be explained by low concentrations of IGF-1R, or IGF-1. 
Hence, there may be a threshold for IGF-1R–mediated activation of Akt. To determine if 
high receptor numbers can promote long-term survival of BLIN-2 in the absence of 
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stromal cell support, future experiments should be performed in which IGF-1R is 
overexpressed in BLIN-2 cells.  
Whereas the first and second possibilities rely on IGF-1R signaling, a third 
possibility is that one or more additional genetic aberrations are required, in addition to 
HoxA9 overexpression, to promote factor independent growth of BLIN-2 cells. Therefore, 
it is important that other models be used to validate findings in BLIN-2, and to rule out 
cell line specific effects.  
We have previously reported that inhibition of PI3K/Akt, MAPK/ERK or the 
Janus protein tyrosine kinases/signal transducers and activators of transcription 
(JAK/STAT) signaling pathways resulted in reduced proliferation of BLIN-2 cells in the 
presence of stromal cell support (194). This effect was more robust when the inhibitors 
were used in combinations. In the same study, inhibition of the PI3K/Akt, MAPK/ERK, 
or JAK/STAT pathways did not result in induction of apoptosis; however, when 
pathways were inhibited simultaneously, there was a marked increase in the number of 
apoptotic events as compared to cells cultured in the absence of stromal cell support after 
24 hr (194). Therefore, stromal cells appear to activate these signaling pathways to 
promote the survival and proliferation of BLIN-2 cells. However, inhibition of a single 
pathway was not sufficient to induce apoptosis, suggesting crosstalk between these 
pathways. Furthermore, these results indicate that activation of PI3K/Akt and 
MAPK/ERK through IGF-1R signaling may not be sufficient alone to alleviate stromal 
cell dependency of BLIN-2. Activation of the JAK/STAT pathway may also be a 
requirement. JAK(s) are non-receptor tyrosine kinases that phosphorylate engaged 
cytokine receptors, allowing for the docking and activation of STAT(s). Subsequently, 
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activated STATs form homo- or heterodimers and translocate to the nucleus to activate 
gene transcription (195). Indeed, constitutive signaling through JAK/STAT is common in 
AML, occurring in up to 70% of AML patients (196,197). 
Leukemias characterized by overexpression of HoxA9 may benefit from IGF-1R 
targeted therapies, in combination with inhibitors of the JAK/STAT pathway, to inhibit 
proliferation and induce apoptosis of leukemic cells. In fact, IGF-1R and JAK/STAT 
targeted therapies may be of particular and immediate benefit in treating leukemias that 
bear MLL translocations. Ten percent of all acute leukemias have MLL translocations and 
80% of infant ALL have MLL translocations (71). The presence of MLL translocations is 
associated with an extremely poor prognosis and there are no therapeutic options for this 
subset (71). Currently there are several IGF-1R inhibitors under clinical investigation, 
though none are approved by the FDA for general oncologic use (198). There are five 
monoclonal antibodies, including: CP-721,871, AMG-479, IMC-A12, R1507, and 
BIIB022; and three small-molecule inhibitors: XL-228, OSI-906, and 
Nordihydroguareacetic acid (NDGA). IMC-A12 is the clinical designation for the A12 
mAb used in the studies presented here, and A12 is currently in phase II clinical trials for 
treatment of cancers of the breast, colon, head and neck, liver, pancreas, prostate, and 
connective tissues (198). Currently, no FDA approved JAK inhibitors are available for 
use in the clinic, although a few are being assessed in phase I and phase II clinical trials, 
including the small molecule inhibitors: AT9283, CEP-701 (lestaurtinib), and MK-0457 
(tozasertib lactate) (199).  
Pim-1 has been reported to be a direct target of HoxA9 transcriptional activity in 
hematopoietic cells (91). Pim-1 phosphorylation of BAD inhibits the initiation of 
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apoptosis (173). In our model, Pim-1 expression was also increased in the presence of 
HoxA9 activity, which was accompanied by increased BAD phosphorylation in the 
absence of growth factor/stromal cell support. This provides a second mechanism by 
which HoxA9 could promote the survival of acute leukemic cells. As such, leukemias 
identified as overexpressing HoxA9, such as those bearing MLL translocations, may 
benefit from inhibitors of Pim-1 activity. Inhibitors of Pim-1 are currently in 
development, and may be available for use in clinical trials in the very near future (176). 
Future experiments to be performed should include the use of Pim-1 siRNA or Pim-1 
inhibitors on BLIN-2/HoxA9:ER cells to evaluate the effects on proliferation on 
apoptotic sensitivity. 
There are likely hundreds of genes regulated by HoxA9 in leukemic cells, yet the 
identification of HoxA9 downstream targets has remained somewhat elusive. At least 220 
candidate genes have been identified, via microarray analysis, to be either upregulated or 
repressed by at least two-fold by HoxA9 in leukemic cells (90). However, very few of 
these candidate genes have been empirically identified as direct downstream targets. 
Some of the targets upregulated by HoxA9 include: signaling molecules, such as EGFR 
pathway substrate 8 (EPS8); enzymes, such as aldehyde dehydrogenase-1 (ALDH1); 
oncogenes, such as v-jun avian sarcoma virus 17 oncogene homolog (c-JUN) and v-yes-1 
Yamaguchi sarcoma viral oncogene 1 (YES1); and regulators of cell cycle progression, 
such as cyclin dependent kinase 7 (CDK7) (90). All of these molecules are associated 
with promoting carcinogenesis (200-204). Therefore, HoxA9 may promote the growth 
and survival of leukemic cells by multiple means. Despite this, identifying intracellular 
pathways activated as the result of HoxA9 overexpression in leukemic cells, rather than 
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specific HoxA9 targets, will provide valuable insight into the mechanisms by which 
HoxA9 promotes the survival and proliferation of leukemic cells. These pathways 
represent potential targets for more effective chemotherapeutic regimens. 
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